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Summary
Niemann-Pick type C (NPC) proteins are essential for sterol homeostasis, believed to drive sterol integration into
the vacuolar/lysosomal membrane before redistribution to other cellular membranes. Here, using a combination 
of crystallography, cryo-electron microscopy, biochemical and in vivo studies on the Saccharomyces cerevisiae 
NPC system, NCR1/NPC2, we present a framework for sterol membrane integration. Sterols are transferred 
between hydrophobic pockets of vacuolar NPC2 and membrane-protein NCR1. NCR1 has its N terminal domain
(NTD) positioned to deliver a sterol to a tunnel connecting NTD to the luminal membrane leaflet 50 Å away. A 
sterol is caught inside this tunnel during transport, and a proton-relay network of charged residues in the 
transmembrane region is linked to this tunnel supporting a proton-driven transport mechanism. We propose a 
model for sterol integration which clarifies the role of NPC proteins in this essential eukaryotic pathway and 
which rationalizes mutations in patients with Niemann-Pick disease Type C.
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INTRODUCTION
Sterols are an essential component of membranes in all eukaryotic cells. In humans, Niemann-Pick type C 
proteins NPC1 and NPC2 bind cholesterol and are essential for lysosomal membrane integration from where 
cholesterol is redistributed to other cellular membranes (Carstea et al., 1997; Loftus et al., 2002; Naureckiene et 
al., 2000). Disturbance of this pathway leads to Niemann-Pick disease Type C, a neurodegenerative disease 
where cholesterols and other lipids accumulate in the lysosomes (Pentchev, 2004). Furthermore, NPC1 has been 
identified as a key virulence factor for the Filoviruses Ebola and Marburg (Carette et al., 2011; Côté et al., 2011).
The molecular mechanism of sterol membrane integration is still unclear, despite having been studied 
extensively. NPC2, a soluble intra-lysosomal protein, binds sterols with distinct polarity (polar head-group 
exposed and aliphatic tail buried in the cavity), and is able to hand-off this sterol to the luminal N terminal 
domain (NTD) of the lysosomal membrane protein NPC1 with reversed polarity (polar head-group buried in the 
pocket) (Deffieu and Pfeffer, 2011; Friedland et al., 2003; Kwon et al., 2009; Wang et al., 2010; Xu et al., 2007). 
Through an unknown mechanism the sterol bound to the NTD is then believed to be passed to the lysosomal 
membrane for integration (Davies and Ioannou, 2000; Davies et al., 2000). Several sterol binding sites have been
suggested in NPC1, and sterol integration into the membrane involves a membrane-buried Sterol Sensing 
Domain (SSD), but the structural and functional relationship between these sites in NPC proteins remains 
unknown (Lu et al., 2015; Ohgami et al., 2004; Ohgane et al., 2013). The luminal side of the lysosomal 
membrane is covered in a ~60 Å thick glycocalyx, a polysaccharide matrix coating which preserves the integrity 
of the lysosomal membrane protecting the cytosol from degradative enzymes inside the lysosome lumen. It has 
been speculated that NPC1 could help sterols bypass this protective layer (Gong et al., 2016; Li et al., 2016a; 
Neiss, 1984; Pfeffer, 2019). In yeast this degradation process is delegated to the vacuole (Schulze et al., 2009). 
The S. cerevisiae NCR1/NPC2 system, located in the yeast vacuole, has been studied extensively to obtain 
insight into the function and dynamics of NPC proteins, and both NPC1 and NPC2 deficient mammalian cells 
can be rescued by the S. cerevisiae counterpart (Berger et al., 2005a, 2005b; Jacquier and Schneiter, 2012; 
Malathi et al., 2004; Munkacsi et al., 2011; Tsuji et al., 2017). The NCR1/NPC2 system shares 32%/22% 
sequence identity with the human system (hNPC1/hNPC2), but there is no structural framework to relate NCR1 
and NPC2 to their human counterparts at the molecular level (Figures S1 and S2A).
Clues to the mechanism of sterol uptake can be found in the cryo-EM structure of the full length hNPC1 (Gong 
et al., 2016), the crystal structure of a large fragment of hNPC1 without the NTD (Li et al., 2016a), and the 
crystal structure of the middle luminal domain (MLD) domain of hNPC1 bound to hNPC2 (Li et al., 2016b). 
Furthermore, recent breakthroughs in the related Patched protein family belonging to the same Resistance-
Nodulation-Division (RND) superfamily as NPC1 proteins, also provide hints towards a possible common core-
mechanism, since Patched is involved in a reverse process of sterol extraction from the membrane (Gong et al., 
2018; Qi et al., 2018a, 2018b; Zhang et al., 2018). Despite this, we do not have a clear understanding of how 
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NPC1 and NPC2 mediate transfer of sterols into the lysosomal membrane, and several different models currently
co-exist (Li et al., 2016a; Pfeffer, 2019; Trinh et al., 2018).
Here we present four structures of yeast NCR1 and NPC2. The crystal structure of NPC2 is solved in both a 
sterol-free and sterol-bound state. We measure sterol binding affinities and demonstrate that sterol transfer is 
possible between NPC2 and the NTD of NCR1. We show that one physiological function of NPC2 and NCR1 is 
to deliver sterols to the vacuole in living yeast cells, in analogy to the human system. The structures of NPC2 
rationalize how sterols are captured and shuttled in the yeast vacuole, and they display an expanded binding site 
compared to its human counterpart indicative of a broader substrate range. We also present the first crystal 
structure, as well as the first single particle cryo-EM structure, of NCR1. Both structures adopt a novel 
conformation not observed in the human NPC1. We identify a tunnel through the central core of NCR1 that links
the NTD with the SSD and in which we observe a bound sterol. Based on our data we propose a mechanism for 
sterol transport where NCR1 can bypass the glycocalyx via a tunnel to mediate sterol insertion into the 
membrane. The model explains puzzling results in the field related to the number of sterol binding sites, and it 
offers a rationale for why the sterol polarity switch from NPC2 to NTD is necessary for proper membrane 
integration in vivo. Finally, our data suggest that the molecular mechanism of sterol transfer and sterol 
membrane integration is conserved from fungi to humans, and offers a rationale for missense mutations found in 
patients with Niemann-Pick Disease Type C.
RESULTS
Structure of sterol-free and sterol-bound NPC2
We expressed, purified and crystallized S. cerevisiae NPC2 (Figure S2B; see also Table S1). The sterol-free form
of NPC2 is determined by experimental phasing to 2.8 Å (Rfree 26.2%) with 3 identical monomers (RMSD(CA) <
0.33 Å) in the asymmetric unit forming a trimer with 120 degree rotational symmetry. In the crystal packing, a 
propeptide (residue 24-34) from one monomer of the trimer extends to fold over a neighboring monomer from 
another trimer (Figure S2C). The NPC2 monomer adopts an open Ig-like beta-sandwich fold with seven anti-
parallel beta-strands (Figure 1A). Strand 1, 2 and 5 form one side of the sandwich while strand 3, 4, 6 and 7 form
the other. A small alpha helix between strand 4 and 5 forms a cover (residues 109-123) enclosing part of a deep 
and elongated hydrophobic cavity (1019 Å3) between the two sides of the sandwich, leaving space for substrate 
entry and exit at only one end of the sandwich. Two disulfide bonds and a single N-linked glycosylation stabilize
the structure.
The structure of NPC2 in complex with sterols was determined to 2.9 Å (Rfree 25.7%) (Figures 1B and S2D; see
also Table S1). The asymmetric unit contains 9 monomers forming 3 trimers similar to the trimer in the sterol-
free structure, but without the propeptide interaction between trimers (Figure S2E). A single ergosterol molecule 
is found in the hydrophobic binding cavity in 5 of the monomers, while the remaining 4 monomers have strong 
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density features in the binding cavity that cannot be confidently classified but appear to be bulkier than 
ergosterol, and may be other lipids (Figure S2F and S2G). The sterol polarity within the cavity is such that the 
polar headgroup points out and the aliphatic tail into the cavity in the same orientation as observed in previous 
human and bovine NPC2 structures (Figure S2H) (Li et al., 2016b; Xu et al., 2007). The sterol resides in a 
hydrophobic cavity lined by the side chains of Pro67, Leu73, Val95, Leu102, Leu103, Ile138, Val142, Tyr147, 
Val149, Val168 and Phe170 some of which form non-specific hydrophobic interactions between NPC2 and the 
sterol (Figure 1C). The cavity is of sufficient size that two sterols could fit side-by-side in the opening, but such 
a setup is not supported by the observed density (Figures S2G and S2I). There is no difference in conformation 
of sterol-free and sterol-bound NPC2 (RMSD(CA) <0.3 Å) (Figure 1B), similar to the bovine sterol-free vs sterol-
bound NPC2 (Xu et al., 2007). While yeast NPC2 has a similar sandwich fold and almost identical binding of a 
single sterol as human and bovine NPC2, the global structure displays significant differences (e.g. to bovine 
sterol-bound form RMSD(CA) 3.0 Å) (Figure S2H). NPC2 has a much larger binding cavity compared to human 
and bovine NPC2 because it lacks a disulfide bond that in the human and bovine NPC2 pushes the beta-
sandwich together opposite the sterol binding site. Furthermore, multiple bulky side chains are facing the cavity 
in both human and bovine NPC2 but not in yeast NPC2, reducing the size of these cavities (e.g. bovine NPC2 
cavity: 186 Å3) (Figures 1D). Despite this, the observed sterol binding site in all three is very similar with respect
to position and orientation of the sterol, with a small difference being a slight tilt of the sterol in yeast NPC2 
compared to bovine and human NPC2 (Figure 1E). It has previously been shown that yeast NPC2 can rescue 
human NPC2-deficient fibroblasts (Berger et al., 2005b), and we can now rationalize this, as essential 
components of sterol binding are conserved between yeast NPC2 and human NPC2.
Sterol binding and transfer by the NCR1/NPC2 system
To establish the binding properties of the NCR1/NPC2 system, we assayed binding affinities of NPC2 and the 
NTD of NCR1 using two different approaches; i) Förster resonance energy transfer (FRET) from aromatic 
residues to an intrinsically fluorescent ergosterol analog, dehydroergosterol (DHE), and ii) binding of 
radiolabeled cholesterol. When exciting NPC2 at 280 nm, sterol binding can be detected as fluorescence of DHE
emitting between 360-400 nm with three characteristic peaks (Figure S3A). This FRET effect from NPC2’s Tyr 
and Phe shows that DHE binds to NPC2 with nanomolar affinity (Kd = 121 nM) (Figure 2A). Using radiolabeled
cholesterol in a different experimental setup, we observe a binding affinity in the same nanomolar range (Kd = 
591 nM) (Figures 2B). Binding competition assays show that the antifungal lipid edelfosine interferes strongly 
with cholesterol binding, while the hNPC1 inhibitor U18666A and the cholesterol trafficking inhibitor 
Cepharanthine inhibit binding more weakly (Figure 2C). In combination with the large binding cavity observed 
in the crystal structure, this data suggests that yeast NPC2 could be involved in general hydrophobic substrate 
trafficking, but this needs to be investigated further in order to identify which substrates it shuttles.
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We expressed and purified NTD and measured DHE binding (FRET) and cholesterol binding (radiolabel) and 
observed similar binding affinities, Kd = 483 nM and 675 nM respectively, with both assays (Figures 2D, 2E and
S3B). Binding competition assays show that the antifungal lipid edelfosine competes strongly with binding of 
radiolabeled cholesterol, while U18666A and Cepharanthine have weaker effects (Figure 2F).
We examined sterol transfer between NPC2 and NTD using FRET. Because NPC2 contains no tryptophans, we 
can specifically measure binding of DHE to NTD when exciting NTD’s Trp at 295 nm (Figures S3C and S3D). 
NPC2 is able to transfer DHE to NTD, while NTD as sterol donor can transfer to NPC2 as well (Figure 2G, S3E 
and S3F). NPC2 is able to transfer radio-labeled cholesterol both to the NTD and to other NPC2 molecules 
(Figure 2H). NTD as a cholesterol donor can transfer to NPC2, and also to other NTD molecules, if somewhat 
less efficiently (Figure 2I). Finally, we reproduced the transfer of cholesterol from NPC2 to NCR1 using full-
length NCR1. We are able to clearly observe a transfer from NPC2 to NCR1 that is dependent on the presence of
the NTD (Figure 2J). These observations for yeast NCR1/NPC2 are comparable to the behavior of the 
hNPC1/hNPC2 proteins underlining the similarities between the two systems (Infante et al., 2008).
Structure of NCR1
The crystal structure of full length NCR1 was solved to 3.5 Å with the asymmetric unit containing a single 
molecule with no indication of oligomerization. The final model is refined to an Rfree of 30.1% and includes 
residues 21-1159 (of 1170 total). The electron density allows unambiguous building of NCR1, except for two 
disordered loops (residues 280-315 and 729-735) (Figure S4A; see also Table S1). The density clearly reveals a 
single bound ergosterol, as well as four N-linked glycosylations and fourteen disulfide bridges in the structure 
(Figure S4B). NCR1 consist of four domains (Figure 3A): the NTD, the transmembrane domain (M2-M13), the 
middle luminal domain (MLD), and the C terminal domain (CTD).
The transmembrane region is comprised of 13 transmembrane helices with M1 in an isolated position. M2-M13 
comprise the transmembrane domain, and here, M2-M7 and M8-M13 share a pseudo two-fold rotational 
symmetry around an axis perpendicular to the membrane (Figure 3B). M3-M7 comprises the canonical sterol 
sensing domain, but structurally it is clear that M2 should also form part of the sterol sensing domain (SSD, 
residues 338-358+530-719) (Figure S4C). This first helix of the SSD was missed in the original sequence 
analysis of SSD-containing proteins due to its lack of proximity to the rest of the SSD in amino acid sequences 
(Hua et al., 1996; Kuwabara and Labouesse, 2002). The SSD has a shelf-like pocket exposed to the outer leaflet 
of the membrane spanned by M2-M5 of sufficient size to harbor a single sterol molecule (Figures 3B, 3C and 
S4C). Two acidic residues are buried in the transmembrane domain, Asp631(M5) and Glu1068(M11) and are 
fully conserved in all NPC family members. In the structure they point towards each other at the center of the 
pseudo-symmetric related transmembrane helices with a distance of 3.9 Å between them, suggesting that either 
or both of these acidic residues are protonated. In close proximity to Asp631 and Glu1068 we find 
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His1072(M11) 3.3 and 2.6 Å away respectively (Figure 3D). Asp631 and Glu1068 are the only conserved and 
buried charged residues in the transmembrane domain, and together with His1072 they form a proton-relay 
network which suggests a functional role of this cluster in NCR1. This is supported by mutagenesis with 
H1072A and D631N mutants both showing a reduction in transfer of cholesterol despite being at a distance of 
around 80 Å from the NTD (Figure 2J). The impact of distant residues in NCR1 on sterol loading from NPC2 
might suggest an allosteric coupling from this transmembrane proton site via the CTD and MLD to the NTD.
The MLD and CTD form a joint structure that point into the lumen of the vacuole with a size that allow it to 
penetrate the glycocalyx. The MLD and the CTD are related by a pseudo two-fold symmetry, with 7 conserved 
secondary structure elements forming a sandwich against each other. Inserted into the sequence of this conserved
sandwich of both MLD and CTD are a region of 80 and 101 amino acids respectively, that form two hyper-
variable regions which are presented to the vacuolar space creating a docking surface to binding partners 
(Figures 3A, S1 and S4D). The MLD and the CTD are attached to the transmembrane domain via four neck 
helices from M2 and M3 to MLD and M8 and M9 to CTD (Figure 3C). The M2 and M8 connections form two 
elongated structures perpendicular to the membrane plane and interact closely with the M5/M11 loops. The two 
'coupling-loops' directly link the MLD and CTD to the central pseudo-twofold acidic pair buried in the 
membrane. Together, the MLD/CTD domains form a luminal core that the NTD docks to at the top of the pseudo
two-fold symmetry point.
The NTD is coupled to the rest of NCR1 via a long linker (~45 Å) that contains three internal disulfide bridges 
and connects via transmembrane helix M1 and a long cytosolic loop to Cytosolic Helix 1 before the SSD (Figure
3A). M1 has a noticeable tilt away from the transmembrane domain towards the cytosolic side. Contact to the 
transmembrane domain is achieved by pi-stacking between Tyr266(M1) and Phe761(M8), and a hydrogen bond 
between Ser259(M1) and the main chain oxygen of Val765(M8) (Figure 3B). The tilt of M1 in hNPC1 is reduced
by about 20 degrees compared to NCR1 (Figure S4E).
The sterol binding core of the NTD is similar to the human NTD with a backbone RMSD(CA) of 2.2 Å. The NTD 
has a clearly defined sterol binding pocket and, as in the cryo-EM hNPC1 structure, the binding pocket is empty 
(Figure S4F). The pocket has a size of 201 Å3, much smaller than the cavity in NPC2, providing an explanation 
for the observed differences in transfer efficiency and competition assays. Compared to the cryo-EM hNPC1 
structure the position of the NTD is significantly different with a rotation of the binding pocket towards the 
MLD/CTD two-fold point of about 20 degrees and a tilt of 40 degrees, which positions the pocket directly 
towards the MLD/CTD two-fold point (Figure 4A). This rotation relative to the MLD/CTD leads to a loop-helix 
motif (residue 157-172) of the NTD moving by ~14 Å towards the MLD/CTD two-fold point, where it now 
forms an interaction surface to the side of the CTD. This weak interaction is mediated mainly by a hydrogen 
bond from Ser162(NTD) to Asn865(CTD) as well as hydrophobic interactions. To test the impact of this 
interaction on NTD's ability to accept sterols from NPC2, we mutated Asn865 of this interaction surface 
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(N865A, removing the hydrogen bond). This mutant display reduced transfer from NPC2 to NCR1 (Figure 4B), 
supporting the notion that this region is involved in the conformational shift of the NTD to accept sterols from 
NPC2. The loop-helix motif starts after a conserved disulfide bridge (Cys101-Cys156) at the end of an alpha 
helix, and ends before a conserved and flexible glycine hinge of 1-3 glycines (residues 173-175) found in all 
NTD domains that appear to help control the movement of the loop-helix motif and the NTD relative to the rest 
of NCR1. We analyzed the glycine hinge both by deletion and by mutagenesis to a tri-alanine stretch and in both 
cases we observed a strong reduction in the ability of NPC2 to transfer sterols to NCR1 (Figure 4B). This is 
consistent with the structural data that suggest a pivotal role of the glycine hinge in the conformational shifts of 
NTD allowing for sterol loading and unloading. The combination of the described M1 tilt and the rotated 
position of the NTD towards the MLD/CTD in our NCR1 structure result in a new conformation with 
implications for the function of these domains in sterol loading.
Recently, structures from the Patched protein family have revealed the presence of a tunnel in the MLD/CTD 
region of Patched through which cholesterol might be transferred (Gong et al., 2018; Qi et al., 2018a; Zhang et 
al., 2018). We find a similar tunnel in NCR1 at the pseudo two-fold symmetry point of the MLD and CTD 
(Figure 4C). The residues comprising the tunnel are the most conserved of NCR1, supporting an indispensable 
role (Figure S5A). The tunnel extends from the membrane leaflet and the SSD shelf to the 157-172 loop-helix 
motif of NTD which are positioned below the tunnel mouth and appear to block it as a gate (Figure 4D). In 
NTD, the sterol binding site is a direct continuation of this tunnel. Inside the tunnel between MLD and CTD we 
observe density for an ergosterol 24 Å from the start of the membrane (Figure 4E). The sterol is positioned with 
the hydroxyl group pointing towards the NTD and the aliphatic chain towards the SSD, which match the polarity
of a NTD deposited sterol released into the tunnel. The polar part of ergosterol does not coordinate to any 
residues, but a small rotation of the nearby Arg950(CTD) could provide an interaction with the hydroxyl group. 
The NTD loop-helix gate appears to prevent sterol back-flow, but it is possible that a sterol could be moved 
around it. The chemical environment of the tunnel does not appear to support fixed binding sites for sterols, but 
rather forms a continuous hydrophobic environment, with a few areas of hydrophilic nature. In support of this, 
the occupancy of the observed sterol refines to 0.87 in the crystal structure, corresponding to a flexible binding 
(Figure S5B). Based on this structural analysis, the crystal conformation of NCR1 represents a “sterol post-
loading state”, where the sterol bound in the NTD has been deposited into the tunnel for transfer to the SSD and 
integration into the membrane. This conformational state is different from the previously reported conformation 
found in the cryo-EM hNPC1 structure, that appears to represent an “empty pre-loading state” ready to accept 
sterols from NPC2 (Gong et al., 2016).
We determined the structure of NCR1 by single particle cryo-EM in parallel with the crystal structure. The 
reconstruction has a global resolution of 7.2 Å including the detergent micelle, with most protein regions 
extending to 5-6 Å (Figure 5). Docking the crystal structure into the EM map, shows strong similarity to the 
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crystallographic model of NCR1 (RMSD(CA) 1.5 Å) (Figure 5C). Interestingly, the NTD is slightly shifted which 
likely relates to the flexible nature of this domain, but it still retains the sterol pocket opening in the same 
position, and the NTD loop-helix gate is unchanged (Figures S5C and S5D). A tunnel between MLD and CTD is
also found in the fitted cryo-EM NCR1 model, but there is no indication of a sterol density in the map, as is 
expected due to the low resolution. Overall, the NTD is in a similar position as in the crystal structure, and 
clearly differs from the cryo-EM hNPC1 conformation (Figure S5E). The cryo-EM structure is free from any 
crystal contacts, supporting that the position of the NTD in the crystal structure is not influenced by crystal 
packing.
NCR1/NPC2 delivers sterols to the vacuolar membrane in analogy with the mammalian system
To determine the physiological function of the yeast NCR1/NPC2 system and its relationship to NPC1/NPC2 in 
mammalian cells we developed an in vivo assay to monitor sterol transport directly from the plasma membrane 
to the vacuole. Sterol transport can be studied using live-cell imaging of the fluorescent ergosterol analog DHE, 
and we hypothesized that aberration of DHE transport could be examined in starved NCR1/NPC2-deficient yeast
cells, when cells become dependent on lipophagy, a special form of autophagy.
Our results show that yeast transport sterols from the plasma membrane to specialized cellular lipid storage 
organelles, called lipid droplets, which become ingested by vacuoles during starvation (Figures 6A and S6). 
NCR1 and NPC2 are required for transfer of sterol from lipid droplets to the vacuolar membrane, as absence of 
either of these proteins result in disposition of DHE in large non-digested lipid droplets inside and outside of 
vacuoles without labeling of the vacuolar membrane (Figure 6). In starved wild type cells, DHE is primarily 
found in the vacuolar membrane with some diffuse staining in the vacuole lumen indicating complete digestion 
of the lipid droplets (Figures 6 and S6). In contrast, in starved cells lacking NCR1 or NPC2, the vacuole is 
fragmented with an irregular shape, and numerous large lipid droplets are found outside and inside the vacuole 
(Figures 6 and S6). The results demonstrate that NCR1- and NPC2-deficient cells internalize lipid droplets into 
their vacuoles, but further processing of lipid droplets and transport of sterols to the vacuolar membrane is 
impaired in vivo.
To probe the effect of pH and proton gradient on this process we next inhibited the vacuolar proton pump using 
Concanamycin A. This result in a vacuolar sterol phenotype identical to the phenotype observed for NCR1- and 
NPC2-deficient cells (Figure 6). These results show that sterol delivery to the vacuolar membrane by the 
NCR1/NPC2 system is instrumental for normal function of the vacuole, and disturbance of the pH environment 
creates an identical phenotype. Analogous observations have been made for mammalian NPC1 underlining the 
similarities between the two systems (Sarkar et al., 2013).
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DISCUSSION
Ligand specificity of NPC2 and NTD and the loading complex of the NCR1/NPC2 system
We report the first structures of both the soluble and membrane integrated components of the yeast sterol-
transporting NCR1/NPC2 system. We show that NPC2 is able to bind sterols in a similar fashion as human and 
bovine NPC2 and with comparable affinity, and that it is able to transfer sterols to the NTD of NCR1. This 
resembles observations made for hNPC2 and for the NTD of hNPC1 (Infante et al., 2008; Kwon et al., 2009).
The ligand competition assays and the large size of the NPC2 cavity further suggest an additional role for NPC2 
as a more general hydrophobic binding partner in the vacuolar environment. The yeast NCR1/NPC2 system 
might transport other lipids besides sterols, and additionally have a more general and promiscuous lipid/sterol 
capture-and-shuttle function inside the vacuole, supported by evidence that NPC proteins interact with other 
cytoplasmic sterol shuttling proteins (Du et al., 2011). NCR1-/- yeast strains are resistant to the lipid-drug 
Edelfosine (Berger et al., 2005a), implying it cannot integrate into the vacuolar membrane unless channeled by 
NCR1, and this is now supported by our observation that both NPC2 and NTD bind Edelfosine.
The position and flexibility of the NTD appear to be a central feature of the function of NPC proteins. A 
NCR1/NPC2 loading conformation requires that the NTD is rotated significantly towards the MLD to receive 
sterols from NPC2. This can be modeled if we rotate NCR1's NTD to match the position found in the hNPC1 
cryo-EM structure in the empty pre-loading state. hNPC2 as well as Ebola virus glycoprotein interact with two 
loops protruding from the variable region of the MLD of hNPC1 (Li et al., 2016b; Wang et al., 2016). However, 
this interaction point is not sufficient to create a tight transfer complex from hNPC2 to the NTD based on the 
structures solved so far, and the residues in the observed MLD/hNPC2 complex do not match residues found to 
be implicated in actual transfer (Gong et al., 2016; Wang et al., 2010). These interacting loops from the variable 
region of the MLD are not conserved from human NPC1 to yeast NCR1 (Figure S5F). It is possible that the 
MLD interaction points identified in the hNPC2/MLD complex represent an early stage of complex formation, 
and also that the yeast system NCR1/NPC2 loading complex is initiated differently.
A tunnel to bypass the glycocalyx and possible active movement of sterols within it
The position of the NTD towards a sterol-loaded MLD/CTD tunnel in NCR1 highlights novel aspects about 
NPC mediated sterol integration into lysosomal/vacuolar membranes. The tunnel explains how sterols bypass the
glycocalyx to reach the membrane for integration by linking the NTD and SSD to each other, and it explains 
several puzzling observations in the NPC family, where data has been inconclusive regarding the number of sites
(e.g. Lu et al., 2015; Ohgami et al., 2004; Ohgane et al., 2013), Patched proteins might employ a related 
transport mechanism, and sterol-like densities have been observed inside analogous tunnels of Patched (Zhang et
al., 2018). There are at least two possible molecular mechanisms that could drive sterol displacement through the
tunnel; either passive diffusion, or active transport mediated by pincer-like movements of the MLD and CTD 
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domains. We show that residues at the proton-relay site influence sterol transfer from NPC2 to full length NCR1,
suggesting that proton translocation could accompany sterol transport by the NCR1/NPC2 system. An active 
mechanism would almost certainly be driven by the coupling loops that connect the MLD and CTD to the 
Asp632/Glu1068/His1072 cluster in the transmembrane region (Figures 3B and 3D). The same mechanism for 
active transport has been proposed for several other proteins that belong to the RND super-family such as 
MmpL3 and HpnN (Kumar et al., 2017; Su et al., 2019; Zhang et al., 2019), and is well characterized in 
particular in the proton driven exporter AcrB (Zhang et al., 2017). In AcrB, conformational changes linking the 
transmembrane region and the extracellular domains have been demonstrated as the primary mechanistic 
parameter for proton-driven transport. AcrB is an obligate trimer and has a transport pathway through a cavity in 
its 'Porter' domain, homologous to the MLD/CTD of NCR1. Importantly, the tunnel we observe in NCR1 is in 
the same location as the AcrB transport pathway (Figure S7) and both published structures of hNPC1 contain 
similar tunnels according to our analysis (Figures S7D and S7E). For NCR1, hNPC1 and Patched the tunnels are
unrestricted, while in AcrB, the tunnel-cavity switches between three conformational steps, depending on the 
protonation state of a transmembrane proton donor/acceptor pair (Asp407/Lys940) located at the transmembrane 
two-fold point. Proton translocation at this proton-relay point result in movement of the transmembrane helices 
and a displacement of the perpendicular coupling helices with consequent changes to the Porter domain (Zhang 
et al., 2017). In NCR1, the corresponding proton-relay residues are the Asp632/Glu1068/His1072 cluster, and 
these 3 central residues of the transmembrane domain are fully conserved in the rest of the NPC family as well 
as the Patched family (Figures 3D, S1 and S7). The NPC and Patched families could use the conserved histidine 
to control pKa of the acidic residues buried here (Buch-Pedersen et al., 2009). In support of this, a comparative 
analysis of Patched with hNPC1 has revealed a displacement of neck helices in both proteins which match 
elements of the proton/substrate transport coupling mechanism found in AcrB (Gong et al., 2018). There is no 
direct evidence for proton translocation as a necessity to drive sterol integration in either the NPC or Patched 
families, but there are some strong indications: 1) In NPC1, a link has been suggested between transmembrane 
movement of charge and transport by demonstrating proton driven transport of oleic acid (Davies et al., 2000). 2)
Inhibiting the V-type ATPase and thereby removing the proton motive force from lysosomal membranes leads to 
cholesterol buildup in the lysosomal lumen (Furuchi et al., 1993; Ouimet et al., 2011; Sarkar et al., 2013). 3) 
Patched transport is highly sensitive to CCCP, a proton motive force decoupler, and the transmembrane mutant 
G509V/D513Y, targeting the transmembrane acidic cluster, has significantly lowered transport of the 
chemotherapeutic agent doxorubicin (Bidet et al., 2012). 4) Our in vivo results demonstrate a strong dependence 
on the pH environment for correct sterol transport to the vacuole membrane (Figure 6) 5) Our biochemical 
results on the proton-relay residues of the transmembrane helix also demonstrate a negative effect on sterol 
transfer by NCR1 (Figure 2J). There is thus indirect but strong evidence of a proton-driven transport mechanism 
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in the literature, which is supported by key elements of our NCR1 structure and by our biochemical and in vivo 
data.
Model of sterol integration into the membrane
Based on the presented results we propose the following model for sterol transport (Figure 7): 1) Sterols in the 
lysosomal/vacuolar lumen are captured by NPC2 with the aliphatic tail buried in the binding cavity. 2) NPC2 
transfers the sterol to the NTD of NCR1 where the sterol binds in the polar opposite direction. 3) The NTD 
rotates to align the NTD binding pocket to the MLD/CTD tunnel which could be linked to the M1 tilt angle. 4) 
The sterol is transported through the tunnel to the SSD shelf likely by pincer movements driven by proton 
interactions with the transmembrane Asp/Glu pseudo-symmetry pair, as controlled by the conserved histidine. 5) 
From the SSD, the sterol diffuses into the outer leaflet of the lipid bilayer, ready for transport to other cellular 
membranes.
There has been an ongoing debate on the mechanism of sterol integration into the lysosomal/vacuolar membrane.
The presented tunnel-based model is distinct to previously proposed models in which the NTD decouples from 
the MLD/CTD upon binding of a sterol and folds in towards the membrane to embed the sterol directly, or via 
the SSD, into the membrane (Li et al., 2016a; Trinh et al., 2018).
Our model is strengthened by the observation that many fungi have the NTD as a separate soluble protein, while 
still retaining NPC2, implying that NPC2 cannot directly deposit its cargo to NCR1 without the NTD being 
present (Adebali et al., 2016). In our model, the transfer from NPC2 to the NTD is needed to reorient the sterol 
allowing it to pass through NCR1 with the aliphatic chain first for integration into the membrane. There are 
studies that show that hNPC2 is able to deposit sterols directly into bilayers, bypassing hNPC1 in artificial 
systems without a glycocalyx (Enkavi et al., 2017; Infante et al., 2008; Xu et al., 2008). We suggest that a first 
basic step in sterol homeostasis is the capture and trafficking of sterol monomers by NPC2 after hydrolysis of 
sterol esters inside the vacuole/lysosome. One major role of NCR1/hNPC1 is to facilitate monomeric sterols 
donated by NPC2 to bypass the glycocalyx for integration into the vacuole/lysosome membrane.
NCR1/NPC2 as a model system for mammalian NPC1/NPC2 and mutations in NPC patients
We found that the NCR1/NPC2 system is required to deliver sterols from lipid droplets to the vacuole under 
starvation conditions of yeast cells. This observation of a NCR1/NPC2 specific yeast sterol storage phenotype 
during lipophagy aligns with recent observations from mammalian cells; macrophages contain sterol rich lipid 
droplets, and the mobilization of this sterol pool requires lysosomal digestion of these droplets during autophagy.
Collapsing the pH gradient across the lysosomal membrane inhibits this process leading to cholesterol build up 
in endo-lysosomes (Furuchi et al., 1993; Ouimet et al., 2011). Mammalian cells lacking NPC1 display impaired 
autophagy with observations of both reduced autophagosome-lysosome fusion and accumulation of lipid 
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droplets. Inhibition of lysosome acidification using bafilomycin A in cells expressing functional NPC1 leads to 
the same phenotype (Sarkar et al., 2013). This is in accordance with our results on the yeast system using a 
NCR1 deficient strain or Concanamycin A. Our results show that the concerted function of the NPC system in 
sterol transport and autophagy is conserved between yeast and mammalian cells, suggesting that an ancient 
evolutionary function of the system might be sterol mobilization during autophagy. In both systems, sterol 
transport strictly depends on an actively maintained proton gradient across the lysosomal/vacuolar membrane, 
strengthening our model of proton-dependent sterol transport by NPC proteins.
Based on our model for transport we can now provide a mechanistic rationale behind defects in single-point 
mutations found in patients with NPC disease. By our survey, there are at least 154 identified missense mutations
in the NPC1 protein that lead to Niemann-Pick disease type C (Table S2). Our structural analysis of the NPC 
disease mutations suggests a direct link to pivotal mechanistic elements of NPC1 sterol transport that we can 
classify into four categories (Figure S7H and Figure S7I): 1) Direct effect on the suggested proton-relay site, 2) 
Interference with the sterol pathway, 3) Interference with the structural elements that link the sterol tunnel to the 
transmembrane proton-relay site driving the suggested pincher movement, and 4) Surface located mutations with
no clear mechanistic implication related to the proposed transport model. This final group is heavily biased 
toward the MLD and CTD domains and could be involved in interaction sites to other proteins, to folding or 
stability. Of the 139 plotted residues, whose mutation leads to NPC disease, 64 are identical between the human 
and yeast NPC systems, and another 23 have conserved biochemical properties (63% total). The most conserved 
residues cluster in regions that we predict to have a functional role (Figure S7H and Figure S7I). This 
emphasizes the functional conservation between the yeast and mammalian systems and supports the similar 
physiological role in the eukaryotic cell we describe above. For instance, the mutation D700N in hNPC1 leads to
a severe form of NPC, and we can now rationalize this with its proposed role at the proton-relay site (Garver et 
al., 2010). The observed structural and mechanistic conservation also rationalize why yeast NCR1 can rescue 
Chinese hamster ovary cells defective for NPC1 (Malathi et al., 2004).
In conclusion, we demonstrate that essential components of the yeast sterol homeostasis system are similar to the
human system. Based on our results, we propose a coherent general mechanism for the integration of sterols into
the membrane by the NPC family which has pinpointed several previously undescribed regions of functional 
interest. Our work establishes a framework for future research, helping the field to address this key eukaryotic 
sterol integration system in a rational manner.
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Main figure titles and legends
Figure 1. Crystal structures of NPC2
(A) Sterol-free NPC2 (rainbow) forms a seven stranded beta sandwich with two disulfide bridges (yellow), 
binding cavity (blue) and internal hydrophobic residues shown.
(B) Sterol-bound NPC2 (orange) overlaid on the sterol-free NPC2 (gray). Ergosterol (purple) binds at the end of 
the hydrophobic binding cavity.
(C) Hydrophobic binding site with ergosterol and residues comprising the binding site, with ergosterol FoFc 
omit map at 3 sigma (green).
(D) Bovine NPC2 with binding caity (blue) and internal hydrophobic residues shown (orientation as panel A).
(E) Comparison of yeast NPC2 and bovine NPC2 binding cavities.
See also Figure S2 and Table S1.
Figure 2. Sterol affinity of NPC2 and NTD and sterol transfer assays
(A) FRET signal shows NPC2 binds Dehydroergosterol (DHE) with a Kd = 121 +/- 75 nM. Data points show 
mean ± SEM of four (n = 4) independent experiments.
(B) NPC2 binds radioactive cholesterol with a Kd = 591 +/- 123 nM. Data points show mean ± SD of four (n = 
4) independent experiments.
(C) NPC2 competition assay. *, P <= 0.05; **, P <= 0.01; ***, P <= 0.001 and ****, P <= 0.0001 by Student’s t 
test. Data for all radiolabeled binding assays are mean ± SD of five (n = 5) independent experiments.
(D) FRET signal shows NTD binds Dehydroergosterol (DHE) with a Kd = 483 +/- 83 nM. Data points show 
mean ± SEM of three (n = 3) independent experiments.
(E) NTD binds radioactive cholesterol with a Kd = 675 +/- 210 nM. Data points show mean ± SD of four (n = 4) 
independent experiments.
(F) NTD competition assay. *, P <= 0.05; **, P <= 0.01; ***, P <= 0.001 and ****, P <= 0.0001 by Student’s t 
test. Data for all radiolabeled binding assays are mean ± SD of five (n = 5) independent experiments.
(G) FRET-based transfer assay of DHE from NTD to NPC2 (full line) and from NPC2 to NTD (dashed 
line).Data points show mean ± SEM of three (n = 3) independent experiments.
(H) Transfer assay with his-tagged NPC2 as donor and untagged NTD (dotted line) or untagged NPC2 (full line) 
as acceptor. Data points show mean ± SD of five (n = 5) independent experiments.
(I) Transfer assay with his-tagged NTD as donor and untagged NTD (full line) or untagged NPC2 (dotted line) 
as acceptor. Data points show mean ± SD of five (n = 5) independent experiments.
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(J) Transfer assay with his-tagged NPC2 as donor and wild type or mutated NCR1 as acceptor. Data points show 
mean ± SD of three (n = 3) independent experiments.
See also Figure S3.
Figure 3. Crystal structure of NCR1
(A) Structure of NCR1 bound to ergosterol (purple). NTD (blue), MLD (yellow), CTD (green cartoon), M1 
(light blue), SSD (orange) and remaining TMs (sand). Insert: Membrane topology diagram of NCR1 show 
conserved and variable regions of MLD and CTD.
(B) Membrane view from vacuolar side with SSD sterol shelf (green). Interactions of M1 and M8 and charged 
residues at the pseudo two-fold (black oval) are shown. M5 and M11 loops and coupler loops are shown.
(C) Membrane view rotated 90 deg. from panel B with SSD sterol shelf (green).
(D) 2FoFc density (1.5 sigma) at the three charged pseudo two-fold residues and alignment of NCR1 (Q12200), 
hNPC1 (Q15118), Human Patched-1 (Q13636) and E. coli AcrB (P31224) of this region.
See also Figures S1, S3 and S5 and Table S1.
Figure 4. NCR1 tunnel with sterol
(A) NTD (blue) view with NTD loop-helix gate (orange) below MLD/CTD pseudo two-fold with glycine hinge 
(pink). Sterol binding pocket points towards the pseudo two-fold. Human NTD (white) is superposed on 
MLD/CTD. The 20 deg. rotation and 40 deg. tilt is marked with arrows.
(B) Transfer assay with his-tagged NPC2 as donor and wild type or mutated NCR1 as acceptor. Data points show
mean ± SD of three (n = 3) independent experiments.
(C) NCR1 (white cartoon) with coupler loops (green and violet), stalks (yellow), NTD loop-helix gate (teal), 
tunnel (red surface) and ergosterol (purple sticks).
(D) Possible route (red) for ergosterol through the NTD loop-helix gate (teal) from NTD (blue) to the tunnel 
between MLD (yellow) and CTD (green).
(E) Ergosterol (purple) with Buster FoFc omit map (2.5 sigma).
See also Figures S5 and S7 and Table S2.
Figure 5. Cryo-EM structure of NCR1 confirms new conformation
(A) Representative micrograph and 2D classes of NCR1.
(B) Cryo-EM reconstruction of NCR1 colored by local resolution.
(C) The crystallographic model fitted by Namdinator to the cryo-EM map.
See also Figure S5.
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Figure 6. Live-cell imaging of sterol transport to the yeast vacuole
(A) Representative images of cells after 48h incubation under starvation conditions for wild-type, ΔNCR1, 
ΔNPC2, or wild-type cells incubated with the vacuolar proton-pump inhibitor Concanamycin A (Con. A). Bar, 5 
µm.
(B) Quantification of sterol enriched and fragmented vacuoles. Data shows mean ± SEM of three or four (n = 3 
except wild-type with n = 4) biological replicates.*, P <= 0.05; **, P <= 0.01; ***, P <= 0.001 by Student’s t 
test.*.
See also Figure S6.
Figure 7. Model of NPC family mediated sterol integration
In pre-loading state (top left), NTD (blue) is ready to receive a sterol. sterol loaded NPC2 docks to MLD 
(yellow) forming the loading complex (top right). The sterol is transferred from NPC2 to NTD. The NTD rotates
so the binding pocket aligns with the tunnel, and the sterol is moved from NTD to tunnel. The sterol is 
transported to the SSD, possibly by movements generated by sequential protonation and deprotonation of the 
charged residues at the transmembrane pseudo two-fold (bottom). The sterol exits at the SSD shelf and 
dissociates into the outer leaflet of the lipid bilayer.
See also Figures S5 and S7 and Table S2.
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Supplemental figure titles and legends
Figure S1. Sequence alignment of S. cerevisiae NCR1 and H. sapiens hNPC1, Related to Figure 3
Alignment between NCR1 (accession number Q12200), and hNPC1 (accession number O15118), based on a 
multiple sequence alignment in Promals3D followed by small manual adjustments based on structural 
comparison. Conserved residues are highlighted with black. Residues that could not be modeled in the structure 
have a gray font. Colored tubes and arrows represent alpha-helices and beta-strands found in NTD (blue), SSD 
(orange), MLD (yellow), Transmembrane region (wheat) and CTD (green). Key residues are labeled below the 
alignment, and elements of interest above the secondary structure designation. NTD-gate is show in orange, 
cytosolic helices in light and dark cyan, coupler loops in green and violet. Signal peptide is highlighted with a 
gray box. The MLD and CTD variable regions are highlighted with dashed lines. 
Residues of the glycine hinge and the transmembrane proton network are highlighted with pink, asparagines 
with observed glycosylation with green, and cysteines involved in disulfide bridges are highlighted with orange.
Figure S2. Sequence alignment and crystal structures of S. cerevisiae NPC2, Related to Figure 1
(A) Alignment between NPC2 (accession number Q12408), and hNPC2 (accession number P61916), based on a 
multiple sequence alignment in Promals3D followed by small manual adjustments based on structural 
comparison. Conserved residues are highlighted with black. Residues that could not be modeled in the structure 
have a gray font. Colored tubes and arrows represent alpha-helices and beta-strands. Signal peptide and pro-
peptide are highlighted with gray boxes. Asparagines with observed glycosylation are highlighted with green and
cysteines involved in disulfide bridges are highlighted with orange.
(B) SDS-PAGE gel of the final sample for crystallization. Crystals of sterol-free NPC2. The black scale bar is 
100 µm. Weighted 2FoFc density of the asymmetric unit, showing the threefold symmetry of the trimer 
contoured at 1.2 sigma
(C) Interaction between propeptide (purple) from symmetry related monomer to chain C (light orange) in sterol-
free NPC2. Chain A and B does not have a similar interaction, and their propeptide cannot be resolved in the 
density.
(D) Crystals of sterol-bound NPC2. The black scale bar is 100 µm. Weighted 2FoFc density of the trimer formed
by chain A, B and C contoured at 1.2 sigma.
(E) Asymmetric unit of sterol-bound NPC2 crystals containing 9 monomers, connected as 3 trimers (A-C, D-F 
and G-I). Five monomers have ergosterol bound (purple). The remaining four have density in the cavity that 
cannot be confidently modeled.
(F) Weighted FoFc density (green) with ergosterol (purple) omitted shown at 3 sigma. To the right is shown a 
Polder map (green) at 6.0 sigma with CC(with ligand, input)=0.84 and CC(without ligand, input)=0.56. The 
difference in polder-map CC support a model with ligand included.
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(G) Weighted FoFc density (3 sigma) in the cavity of chain A and chain H of sterol bound NPC2. The sterol of 
chain A was omitted before refinement and map calculation. Density in chain A show a single sterol molecule, 
while the density in chain H could not be confidently modeled.
(H) Overlay of human (dark gray) and bovine (white) NPC2 with yeast sterol bound NPC2 (rainbow). Ergosterol
from the NPC2 structure is shown (purple) together with cholesterol sulphate (white and dark gray) from the 
human and bovine structures.
(I) There is space enough for an additional sterol in the yeast NPC2 cavity as illustrated by in silico modelling of
an additional ergosterol into the pocket (white).
Figure S3. Spectral data for DHE binding and transfer assays, Related to Figure 2
(A) Spectral data for DHE binding to NPC2 as shown in Figure 2A. NPC2 has a characteristic peak at 305 nm, 
which stems primarily from Tyr residues (no Trp is present in NPC2). Binding of the naturally occurring 
intrinsically fluorescent ergosterol analog dehydroergosterol (DHE) leads to aromatic residue fluorescence 
quenching at 305 nm and additionally gives a characteristic peak at DHE’s emission between 365 and 425 nm, 
which is characteristic for Förster resonance energy transfer (FRET) from aromatic residues to DHE. Each trace 
is the average of 3 individual measurements and the standard error of the mean (SEM) is shown. The binding 
curve in Figure 2A is derived from the FRET signal at 375 nm.
(B) Spectral data for DHE binding to NTD as shown in Figure 2D. NTD has a characteristic emission at 330 nm 
generated primarily by Trp residues in the protein which is quenched by DHE binding while FRET leads to 
increase in DHE emission between 365 and 425 nm. Each trace is the average of 3 individual measurements and 
the SEM shown. The binding curve in Figure 2D is derived from the FRET signal at 400 nm.
(C) Emission spectra of 1.0 µM NPC2 in the absence (black line) or presence (red line) of 1.0 µM DHE added 
from an ethanol stock solution as described in Methods. Spectra for background (binding buffer for black line 
and binding buffer with 1.0 µM DHE for red line) were acquired separately and subtracted from the 
measurements. The spectra show that there is no FRET from NPC2 to DHE when exciting at 295 nm.
(D) Excitation spectra of 1.0 µM NPC2 (emission at 305 nm; black curve) and of 1.0 µM NTD (emission at 330 
nm; red curve) [both in the presence of 1 µM DHE]. Both proteins show excitation maxima at 232 nm (from the 
protein backbone) and around 270-280 nm stemming from aromatic residues. However, only NTD can be 
excited at 295 nm, where excitation of NPC2 is close to zero (blue arrows). At 295 nm Trp residues but no Phe 
or Tyr residues absorb, which allows for selective excitation of NTD. The inset shows the wavelength range 
between 270-298 nm enlarged. All spectra are selective examples from 2-4 repetitions.
(E) Spectral data for DHE transfer from NTD to NPC2 as shown in Figure 2G. NTD in Tris buffer (1.0 µM; 
black line) was pre-incubated with 1.0 µM DHE (blue line) followed by addition of 0.1 µM (red line) or 2.0 µM 
(green line) NPC2. NTD shows FRET to DHE, when excited at 295 nm, which does not excite NPC2. This 
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FRET signal decreases as function of NPC2 concentration and gave for 390 nm the transfer curve shown in 
Figure 2G. All spectra were corrected for the respective buffers.
(F) Spectral data for DHE transfer from NPC2 to NTD as shown in Figure 2G. 1.0 µM NPC2 in Tris buffer was 
pre-incubated with 1.0 µM DHE followed by addition of 0.1 µM (black line), 0.5 µM (red line), 1.0 µM (green 
line) or 2.0 µM (yellow line) NTD. NTD shows FRET to DHE, when excited at 295 nm, which does not excite 
NPC2. This FRET signal increases as function of NTD concentration and gave for 390 nm the transfer curve 
shown in Figure 2G. All spectra were corrected for the respective buffers.
Figure S4. Crystal structure of NCR1, Related to Figure 3
(A) SDS-PAGE gel of the final sample for crystallization, and the mutants of NCR1 used for transfer assays. 
Several additional mutants in the loop-helix and tunnel regions were expressed for biochemical assays but 
resulted in aggregation (data not shown). LCP crystals of NCR1. The black scale bar is 100 µm. Weighted 2FoFc
density at 1.2 sigma of the asymmetric unit.
(B) Disulfides (yellow) and glycosylations (green) present in the NCR1 structure.
(C) Zoom in on the SSD shelf (red volume) surrounded by M2-M5 with an ergosterol molecule shown to scale 
next to the structure.
(D) Superposition of MLD (yellow) and CTD (green) with the variable regions shown in full colors and the 
sandwich part shown in pale colors. Insert: Membrane topology diagram of NCR1 highlight conserved and 
variable regions of the MLD and CTD.
(E) Tilt of M1 of NCR1 (blue) compared to hNPC1 (red). The structures are superposed on the transmembrane 
domain.
(F) The sterol binding pocket of the NTD of NCR1 (blue) next to the NTD from human NPC1 (red). The loop-
helix motif is shown in orange.
Figure S5. Analysis of NCR1 structure, Related to Figure 3, Figure 4, Figure 5 and Figure 7
(A) Conservation of the residues in NCR1 using 94 homologous sequences as identified by Consurf. The 
residues of the SSD shelf and lining the tunnel are highly conserved.
(B) Weighted FoFc omit maps (green mesh) of ergosterol (purple model) calculated with phenix and Buster 
shown at 2.5 sigma. The Polder map (green mesh) is contoured at 4.5 sigma with CC(with ligand, input)=0.80 
and CC(without ligand, input)=0.66. The difference in polder-map CC support a model with ligand included.
(C) Superposition of the NCR1 Cryo-EM fitted model (blue) and the NCR1 crystal structure (white).
(D) Zoom in on the NTD (from panel C) shows no tilt, but a ~15 deg rotation of the NTD, with the loop-helix 
motif stays in the same position.
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(E) Superposition of hNPC1 (3JFD8) to the Cryo-EM fitted model of NCR1 with a zoomed view on the NTD 
displays the same rotation and tilt as seen in Figure 4A. This rotation and tilt changes the relative position of the 
sterol binding pocket so that in hNPC1 it points towards the MLD and is further exposed to the lumen.
(F) Superposition of MLD from crystal structure NCR1 (yellow) and hNPC1 (red) with the variable regions 
shown in full colors and the sandwich part shown in pale colors. The loops in the variable region of hNPC1 
found to interact with NPC2 in the complex structure (5KWY) does not appear conserved from hNPC1 to 
NCR1.
Figure S6. Sterol transport from the plasma membrane to the vacuole depends on NCR1/NPC2, Related 
to Figure 6
(A-B) Wild-type (A) and NCR1-deficient (B) yeast were labeled with 20 μg/mL DHE and 1 µg/mL FM4-64 for 
22h in an anaerobic chamber at 30°C, washed and cultured without dilution under aerobic growth conditions in 
their original growth medium for further 0.5, 6, 24 and 48h. This procedure ensured starvation conditions 
throughout the whole experiment. DHE is initially, after switch to aerobic growth, found in the plasma 
membrane and few intracellular spots, while the sterol accumulated in lipid droplets surrounding the vacuole 
after 6h incubation in both cell types. Some DHE lacking the droplet marker was also found inside the vacuole. 
After 24h and 48h of incubation, DHE was found in lipid droplets stained with BODIPY as described in 
Materials and Methods. Sterol-containing lipid droplets merged with the vacuole, and DHE was observed inside 
the vacuole lumen and along the vacuolar membrane in wild-type cells (A). In contrast, in NCR1-deficient cells, 
DHE accumulated at 24h and 48h in large punctate lipid droplets containing BODIPY outside and inside the 
vacuole, which appeared fragmented and multivesicular (B).
(C-D) Vacuoles stained with FM4-64 and associated with BODIPY labeled lipid droplets were imaged on a 
confocal microscope operating in z-sectioning modus. Individual planes being 0.3 µm apart are shown through 
the entire volume of the vacuoles. While the vacuole in wild-type cells (upper panel) is round and contains 
numerous small and weakly stained BODIPY patches, that in NCR1-deficient cells (lower panel) is multi-
vesicular and contains many large lipid droplets, brightly stained with the BODIPY dye. D, vacuolar phenotypes 
were scored by confocal microscope from a single experiment carried out in duplicate with >30 vacuoles per 
condition. Four sub-types were distinguished; droplets inside and at rim of round vacuole (I), lipid droplets only 
at rim of round vacuole (II), lipid droplets only outside of round vacuole (III) and fragmented multi-vesicular 
bright with multiple large lipid droplets (IV). While wild-type cells primarily had type I and II vacuoles, NCR1-
deficient fibroblasts had most vacuoles of type III and IV. 
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Figure S7. Comparison of NCR1 to hNPC1, AcrB and Patched-1 and NPC disease mutations plotted, 
Related to Figure 4 and Figure 7
(A-E) Tunnel (red) through NCR1 (orange), AcrB (4DX5, green), Patched-1 (6DMB, yellow), hNPC1 crystal 
structure without NTD (5U74, purple) and hNPC1 cryo-EM structure (3JD8, purple). Below each structure is a 
zoom in panel of the residues implied in proton coupling with distances shorter than 3.8 Å. For AcrB, only chain 
B is shown as this is the conformation with the longest opening of the Porter domain tunnel/transport cavity. 
Compared to the eukaryotic RND tunnels, the AcrB tunnel is mirrored in AcrB along the pseudo two-fold.
(F) Alignment of the transmembrane domains of the structures listed in A-E show the residues implicated in 
proton coupling to all be in similar positions.
(G) Human NPC1 (3DJ8) contain large deviations in the model, with most of the Sterol Sensing Domain having 
residues shifted by over 10 positions compared to the hNPC1 crystal structure (5U74). Sequence alignment to 
NCR1 and sequence membrane topology prediction services confirm these deviations of the model 3DJ8. In 
green are shown positions that agree with 5U74. Yellow regions have a frameshift of 1 residue. Orange regions 
have frameshifts of between 2 and 9 residues. Red regions have frameshifts of 10 to 20 residues.
(H) Missense mutations related to Niemann-Pick disease Type C plotted on NCR1, and colored by conservation: 
identical (red), functionally conserved (orange) and not conserved (wheat).
(I) Same mutations as in panel H, now colored by likely interference to functional categories: protonation site 
(red), pincer movement (blue), sterol pathway (orange) and stability/folding (green).
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STAR Methods
KEY RESOURCES TABLE
[see separate document]
LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the 
Lead Contact, Bjørn P. Pedersen (bpp@mbg.au.dk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
The S. cerevisiae expression strain DSY-5 (Gentaur) is propagated by growth in standard Yeast Extract–Peptone–
Dextrose (YPD) liquid media, grown at 30o C at 150 rpm.
All strains for in vivo assays were generated in the BY4741 or BY4742 background. BY4741 (WT) cells were 
obtained from the Euroscarf culture collection (http://www.euroscarf.de). The CBY5147 (BY4742 
ncr1Δ::KanMX4) and CBY5340 (BY4742 npc2Δ::KanMX4) were kindly provided by Prof. Christopher Beh, 
Simon Fraser University, Burnaby, Canada but originally obtained from the Open Biosystems deletion collection
(https://dharmacon.horizondiscovery.com/). For each experiment, cells were first grown overnight on a solid 
YPD agar plate containing G418 (200 µg/mL). Subsequently, single colonies of the BY4741 (WT), CBY5147 
and CBY5340 strains were grown in 5 ml YPDade media (2% glucose, 2% peptone, 1% yeast extract, 0.02% 
adenine) in a 50-ml Falcon tube at 30o C at 150 rpm, until they reached stationary phase.
METHOD DETAILS
PROTEIN EXPRESSION
Genes encoding the Saccharomyces cerevisiae NCR1 (Accession number Q12200), NCR1_NTD (aa 1-244) and 
the Saccharomyces cerevisiae NPC2 (Accession number Q12408) were introduced into an expression construct 
based on p423_GAL1 (Mumberg et al., 1994) with a C-terminal purification tag containing a thrombin cleavage 
site and a deca-histidine tag. The NCR1, NCR1_NTD and NPC2 constructs were transformed into the S. 
cerevisiae expression strain DSY-5 and grown in a culture vessel to high density by fed-batch and harvested after
a 22 hrs induction using galactose (Lyons et al., 2016). Harvested cells were washed twice in cold water (3,300 
g, 10 min spin) and stored at –80o C. For cell lysis, cells were thawed and re-suspended in 750 mL Lysis buffer 
(600 mM NaCl, 100 mM Tris pH 7.5, 1 mM PMSF), followed by 4x1 min cycles of bead-beating with 0.5 mm 
glass-beads. Lysed cells were spun (21,000 g, 20 min) to pellet cell debris and unlysed cells. The supernatant 
was spun at 20,4526 g for 2 hrs to pellet membranes. When isolating NCR1_NTD and NPC2 the supernatant 
was used downstream, whilst for the membrane protein NCR1 the pelleted membranes were homogenized in 
Membrane buffer (500 mM NaCl, 50 mM Tris pH 7.5, 20% glycerol) and flash frozen in liquid nitrogen.
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PROTEIN PURIFICATION
Purification of full length NCR1
NCR1 membranes were solubilized for 30 min in Basis Buffer (500 mM NaCl, 50 mM Tris pH 7.5, 10% 
glycerol, 20 mM imidazole) with 0.6 % n-Dodecyl-β-D-Maltopyranoside (DDM) and 1.5 mg/mL iodoacetamide 
at 4o
 
C. The solubilized sample was loaded on a 5mL HisTrap HP column equilibrated in Wash Buffer (500 mM 
NaCl, 50 mM Tris pH 7.5, 10% glycerol, 20 mM imidazole, 0.017% DDM). After loading the column was 
washed with ~12 column volumes (CV) W70 Buffer (500 mM NaCl, 50 mM Tris pH 7.5, 10% glycerol, 70 mM 
imidazole, 0.017% DDM), followed by ~9 CV of G20 buffer (200 mM NaCl, 20 mM Tris pH 7.5, 20 mM 
imidazole, 0.05% w/v Decyl Maltose Neopentyl Glucol (DM-NG)). Finally, 5 mL of G20 buffer with 175 units 
of bovine thrombin and 2000 units Endo-H was circulated over the column ON. The following day the protein 
was eluted in ~5 CV of G40 buffer (200 mM NaCl, 20 mM Tris pH 7.5, 40 mM imidazole, 0.01% w/v DM-NG) 
and concentrated on a 20 mL Vivaspin concentrator (100 kDa cutoff) to < 500 µL. The sample was loaded on a 
Superdex200 10/300 GL Increase column equilibrated in G-Buffer (200 mM NaCl, 20 mM Mes pH 6.5, 0.01% 
w/v DM-NG). The composition of the G buffer was optimized through a thermostability assay (Tomasiak et al., 
2014). Peak fractions were collected and concentrated to ~500 µL total volume before adding 20 µL PNGase F 
and incubating at 4ºC overnight. The following day the sample was again loaded on a Superdex200 10/300 GL 
Increase column equilibrated in G-Buffer as before. Peak fractions were pooled and concentrated to ~10 mg/mL 
and stored on ice until used for crystallization trials.
Purification of NPC2 for crystallization
The supernatant from lysed S. cerevisiae cells expressing NPC2 was mixed with imidazole to a final 
concentration of 20 mM and the pH was adjusted to pH 7.5 by adding Tris-HCl pH 7.5. The supernatant was 
loaded on a 5 mL HisTrap HP column equilibrated in Wash Buffer (500 mM NaCl, 50 mM Tris pH 7.5, 10% 
glycerol, 20 mM imidazole). The column was washed with ~20 CV W70 Buffer (500 mM NaCl, 50 mM Tris pH
7.5, 10% glycerol, 70 mM imidazole) followed by ~9 CV of G20 buffer (200 mM NaCl, 20 mM Tris pH 7.5, 20 
mM imidazole). When crystallizing the sterol/lipid free form of NPC2 the W70 buffer also contained 0.017% 
DDM to remove bound lipids/sterols. Finally, 5 mL of G20 buffer with 175 units of bovine thrombin and 2000 
units Endo-H was circulated over the column ON. The protein was eluted with ~5 CV of G40 buffer (200 mM 
NaCl, 20 mM Tris pH 7.5, 40 mM imidazole) and concentrated on a 20 mL Vivaspin concentrator (10 kDa 
cutoff) to < 500 µL. The sample was loaded on a Superdex75 10/300 GL column equilibrated in G-Buffer (200 
mM NaCl, 20 mM Tris pH 7.5). Peak fractions were collected and concentrated to ~10 mg/mL.
Purification of NCR1_NTD and NPC2 for binding and transfer assays
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For binding assays, purification of NPC2 and NCR1_NTD followed the same general protocol as in 
“Purification of NPC2 for crystallization” above, but without removal of the His-tag. In brief, after washing 20 
CV with a modified W70 buffer (containing 0.017% DDM to remove lipids/sterols), the protein was 
immediately step eluted with 7 CV Elu500 Buffer (200 mM NaCl, 20 mM Tris pH 7.5, 500 mM imidazole), and 
relevant fractions were pooled and buffer exchanged into G-Buffer (200 mM NaCl, 20 mM This pH 7.5) while 
being concentrated on a 20 mL Vivaspin concentrator (10 kDa-cutoff) to < 500 µl. The sample was loaded on a 
Superdex75 10/300 GL column equilibrated in G-Buffer. Selected fractions were pooled and stored on ice until 
used for assays.
STRUCTURAL DETERMINATION
Crystallization and data processing of NCR1
Lipid mix was prepared by mixing 50-75 mg Monoolein with 1,2-dioleoyl-sn-glycero-3-phosphocholine 
(DOPC) in a 1:10 weight ratio. Ergosterol was solubilized in chloroform and added to the mixture to a final 
concentration of 0.5% w/w. The chloroform was evaporated, and the lipid mixture heated to 42ºC and mixed 
with protein (3:2 w/w) using a Hamilton syringe to create the LCP. 50 nL drops of LCP plus 1 µL screen were 
pipetted to crystallization plates (Gryphon, Art Robins Instruments) and stored at 18ºC. The final crystal 
conditions were: 14-18% w/v pentaerythritol propoxylate (5/4 PO/OH), 100 mM MES pH 6.1, 87.5 mM NH4Cl, 
8-14 mM MnCl2. One day before fishing crystals, the reservoir solution was exchanged with a similar solution 
containing an additional 20% w/v pentaerythritol propoxylate (5/4 PO/OH). 10 min before fishing the trays were
transferred to 4o C and crystals fished using Dual Thickness MicroMounts from MiTiGen. Datasets were 
collected at beamlines I04, I04-1, I24 (DLS), BioMAX (MAX IV), P14 (DESY-PETRA III) and PXI (SLS). 
Data was processed and scaled with XDS (Kabsch, 2010). The phase problem was solved by Molecular 
Replacement in Phaser (McCoy et al., 2007) using a chimeric Phenix sculptor (Bunkóczi and Read, 2011) model
based on hNPC1 without the NTD (pdbid: 5U73) and the isolated NTD domain (pdbid: 3GKH). This initial 
NCR1 model resulted in very poor quality maps, where only few secondary elements were visible, but it could 
be improved by a combination of Rosetta optimization in phenix.rosetta_refine (DiMaio et al., 2013) and 
Molecular Dynamics based geometry optimization using MDFF (Trabuco et al., 2008) through Namdinator 
(Kidmose et al., 2018). Following this optimization, the model was built in COOT (Emsley et al., 2010) guided 
by 2mFo-DFc maps, Staraniso (Tickle et al., 2018 (Global Phasing Ltd.)) 2mFo-DFc maps and Feature 
Enhanced Maps (Afonine et al., 2015), and refined using phenix.refine (Adams et al., 2010) and Buster (Smart et
al., 2012). Final refinement in phenix.refine was done with a refinement strategy of individual sites, individual 
ADP, group TLS and group occupancy for the sterol ligand, against a maximum likelihood (ML) target using 
reflections from the unmodified XDS dataset in the 50–3.5 Å range. The final model resulted in electron density 
maps of high quality, and yielded an Rwork of 26.6% and an Rfree of 30.1% (Supplementary Table 3). 
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MolProbity (Chen et al., 2010) evaluation of the Ramachandran plot gave 92.1% in favored regions and 0.2% 
outliers.
Cryo-EM data acquisition, image processing and 3D reconstruction for NCR1
For cryo-EM, 3.5 µL of purified NCR1 at ~1 mg/mL concentration were applied on glow-discharged grids 
(Quantifoil R1.2/1.3). The grids were blotted using a Vitrobot Mark IV (FEI) with 6 s blotting time at 100% 
humidity and plunge-frozen in liquid ethane. A total of 2,706 movies were recorded on a Titan Krios electron 
microscope (Thermo Fisher Scientific - FEI) operating at 300 kV at a magnified pixel size of 1.047 Å. 
Micrographs were recorded using a K2 Summit direct electron camera (Gatan) with defocus values ranging from
1.5 µm to 3.5 µm. The total exposure time was 15 s resulting in an accumulated dose of ~60 e-Å2 and a total of 
24 frames per micrograph. Automatic data acquisition was carried out in EPU (Thermo Fisher Scientific - FEI). 
Micrographs were subjected to beam-induced motion correction using MotionCor2 (Zheng et al., 2017). CTF 
parameters for each micrograph were determined by CTFFIND4 (Rohou and Grigorieff, 2015). 73,423 particle 
images were manually picked and subjected to 2D and 3D classification within RELION 2.1 (Fernandez-Leiro 
and Scheres, 2017). From this step, 33,062 particles belonging to a single 3D class were selected for further 
processing. Focussed classification on the soluble portion of the reconstruction led to a homogeneous 20,535 
particle subset. 3D auto-refinement within RELION produced a reconstruction with a global resolution of 7.2 Å, 
with significant regions extending to ~5.6 Å. Local resolution was determined using RELION with half map 
reconstructions as input maps. The crystal structure of NCR1 was fitted into the cryo-EM map by Molecular 
Dynamics Flexible Fitting (Trabuco et al., 2008) using Namdinator (Kidmose et al., 2018).
Crystallization and data processing of NPC2
To obtain crystals of NPC2, 200 nL reservoir + 200 nL of 10 mg/mL protein sample was set up using a Mosquito
liquid handler (TTP Labtech) in a vapor diffusion setup. Crystals appeared at 19ºC after 4 days using a reservoir 
of 200 mM Ammoniumcitrate dibasic pH 5.1, 20% PEG-3350. Crystals of the sterol-bound NPC2 appeared at 
19ºC after 2 days in 800 mM Lithium sulfate monohydrate, 100 mM Sodium acetate trihydrate pH 4.0, 4% PEG-
200. For experimental phasing, crystals of sterol-bound NPC2 were soaked with Ta6Br12 for 1 hour before 
fishing. Datasets were collected at beamlines I04 (DLS), Biomax (MAX IV) and ID23-1 (ESRF). All data was 
processed with XDS. To solve the phase problem for NPC2, a deep search was performed using phenix.hyss 
(Grosse-Kunstleve and Adams, 2003) using both the sterol-bound (P61) and sterol-free (P61) dataset, resulting in 
a substructure solution with a total of 19 Ta sites in the sterol-bound P61 dataset. Initial SIRAS phases were 
calculated with MLphare (Winn et al., 2011) and the substructure refined using isomorphous differences (xyz, 
occupancy and B-factors). To improve the phases, density modification using histogram matching, solvent 
flattening and phase extension was done in DM (Cowtan, 1994). This resulted in initial maps of very poor 
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quality where however 9 monomers could be identified. A homology model made with SwissModel (Waterhouse
et al., 2018) based on Lymphocyte antigen 86 (pdbid: 3T6Q) was fitted manually into the 9 monomer sites and a 
new solvent mask was made with NcsMask (Winn et al., 2011) and used together with histogram matching in 
DM to improve on the phases. By fine-tuning the relative position of the monomers manually, initial NCS 
operators were obtained from the model with phenix.find_ncs and used to average the density with 
phenix.ncs_average. After rebuilding the best defined monomer, a single monomer was then used as a search 
model in a second Ta6Br12 soaked sterol-bound P62 dataset (3 monomers in the asymmetric unit) and two Ta6Br12 
sites were found using Phaser-EP (McCoy et al., 2007). After NCS averaging, solvent flattening and histogram 
matching in phenix.resolve (Terwilliger, 2001) the model was rebuilt in Coot and refined in phenix.refine. The 
dataset was severely anisotropic and Staraniso scaling helped significantly to guide model building. After 
refining, a single monomer was used as a search model in Phaser on the sterol-free P61 dataset (3 monomers in 
the asymmetric unit). After this, completion of the model and final refinement in phenix.refine was done with a 
refinement strategy of individual sites, individual ADP, torsion-angle NCS restraints, and group TLS (1 per 
chain) against a maximum likelihood (ML) target with reflections in the 49–2.8 Å range. The final model of 
sterol-free NPC2 resulted in an Rwork of 23.6% and an Rfree of 26.2%. MolProbity evaluation of the 
Ramachandran plot gave 96.0 % in favored regions and 0.5% outliers.
A single monomer from the final sterol-free NPC2 structure was then used as a search model in Phaser on the 
sterol-bound P61 dataset (9 monomers in the asymmetric unit). Final refinement in phenix.refine was done with a
refinement strategy of individual sites, torsion-angle NCS restraints, individual ADP and group TLS (1 per 
chain) against a maximum likelihood (ML) target with reflections in the 49–2.9 Å range. The final model 
resulted in an Rwork of 22.6% and an Rfree of 25.7%. MolProbity evaluation of the Ramachandran plot gave 
97.0% in favored regions and 0.1% outliers.
Structural analysis and visualization
All structural figures were prepared using PyMOL 1.5.0.4 (The PyMOL Molecular Graphics System 
(Schrödinger LLC, 2012) or VMD 1.93 (Humphrey et al., 1996). Conservation of residues between homologous 
sequences was determined using Consurf with default settings (Ashkenazy et al., 2016). Cavities in NPC2 were 
characterized using CASTp with a probe radius of 1.4 Å, equivalent to the radius of water (Tian et al., 2018). 
The tunnel through NCR1 was identified with MOLE2.0 (Sehnal et al., 2013) using default settings and a probe 
radius of 1.4 Å. Sequence alignments were constructed with PROMALS3D (Pei et al., 2008), followed by 
manually refining gaps based on the observed structure. Alignments were visualized using ALINE (Bond and 
Schüttelkopf, 2009).
BINDING AND TRANSFER ASSAYS
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Radiolabeled sterol binding assay
His-tagged NPC2 or His-tagged NCR1_NTD samples were diluted into Binding Buffer (200 mM NaCl, 50 mM 
Mes pH 5.5, 0.004% w/v TritonX-100) and mixed in tubes at a final concentration of 75 nM with cholesterol, 
solubilized in Binding buffer (1600 nM cold cholesterol (from 0.1 mg/mL in ethanol stock) and 400 nM [1,2-
3H(N)] cholesterol from Perkin Elmer[40-60Ci/mmol] in chloroform), at 50, 100, 150, 350, 550, 750 and 1250 
nM concentration. Final volume was adjusted to 200 µL for each reaction with Binding buffer, and triplicates 
were made for each concentration of cholesterol. Control triplicates were made for each of the above stated 
concentration of cholesterol in the absence of protein. The values obtained in the control triplicates were later 
subtracted from the measurements with protein present. The samples were gently vortexed and then incubated at 
room temperature overnight which ensured complete equilibrium of ligand binding. Next day, nickel resin was 
washed in Binding buffer 2 (200 mM NaCl, 80 mM Tris pH 7.5, 20 mM imidazole, 0.004% w/v TritonX-100) 
and 30 µL of 50% resin slurry was transferred to each sample with 400 µL High pH Buffer (200 mM NaCl, 80 
mM Tris pH 7.5, 20 mM imidazole, 0.004% w/v TritonX-100). Following 1 hour binding, the resin was pelleted 
(700 g) and washed twice with 600 µL Wash Buffer (200 mM NaCl, 20 mM Tris pH 7, 60 mM imidazole, 
0.004% w/v TritonX-100). After the last wash the resin was pelleted and the protein eluted by adding 500 µL of 
Elution buffer (200 mM NaCl, 20 mM Mes pH 5.5, 300 mM imidazole). The eluted protein was isolated by a 
final 700 g spin and moved to another tube. Scintillation liquid was added and the scintillation was measured on 
a Scintillation Counter (Tri-Carb 2810 TR, Perkin Elmer).
Radiolabeled sterol competition assay
The competition assay followed the same general protocol as in “Radiolabel sterol binding assay”. Competitors 
were solubilized in ethanol at 1 mg/mL and added to separate tubes with Binding Buffer (200 mM NaCl, 50 mM 
Mes pH 5.5, 0.004% w/v TritonX-100) to a concentration of 20 µM. All tubes were added ethanol to ensure 
same total amount ethanol (1.5% final concentration of ethanol). 150 nM of His-tagged NPC2 or NTD was 
incubated overnight at room temperature with 1.5 µM [1,2-3H(N)] cholesterol in Binding Buffer (200 mM NaCl,
50 mM MES pH 5.5, 0.004% w/v TritonX-100) and 7.5 µM (5x) of either cold cholesterol, ergosterol, 
edelfosine, U18666A or cepharanthine followed by nickel pulldown.
Radiolabeled sterol transfer assay for soluble proteins NPC2 and NTD
For transfer assays, protein with and without His-tag was purified according to the two different protocols, and 
always with 0.017% DDM in the W70 buffer to ensure the sterol binding sites would be empty. His-tagged 
NPC2 or His-tagged NCR1_NTD was mixed with cholesterol and prepared as described in the “Radiolabel 
sterol binding assay” protocol above, but with 750 nM protein per tube and 3000nM cholesterol (2400 nM cold 
cholesterol and 600 nM [1,2-3H(N)] cholesterol [40-60 Ci/mmol) to obtain the sterol-donor sample. Following 
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elution with Elution Buffer 2 (200 mM NaCl, 20 mM Mes pH 5.5, 300 mM imidazole pH 5.5, 0.004 w/v% 
TritonX-100), 50 pmol sterol-donor protein was transferred to new tubes and added 25 pmol, 75 pmol and 150 
pmol of sterol-acceptor protein (untagged NPC2 or NCR1_NTD) in Binding Buffer, and the total volume was 
adjusted to 300 µL with Binding Buffer. The samples were incubated for 3 hrs at 4ºC with gentle shaking. Nickel
resin was washed in High pH Buffer (200 mM NaCl, 80 mM Tris pH 7.5, 20 mM imidazole, 0.004% w/v 
TritonX-100), and 60 µL of 50% resin slurry was transferred to each sample with 340 µL High pH Buffer (200 
mM NaCl, 80 mM Tris pH 7.5, 20 mM imidazole 0.004% w/v Triton X-100). Following 1 hour binding at 4ºC, 
the resin was pelleted (700 g) and the supernatant containing the sterol-acceptor protein from each tube was 
removed and added scintillation liquid. The pelleted resin containing the sterol-donor protein was resuspended 
with Elution Buffer and transferred to a new tube and added scintillation liquid. Both were measured in order to 
quantify the total amount of radioactivity per sample.
Radiolabeled sterol transfer assay for membrane protein NCR1 and soluble NPC2
His-tagged NPC2 was purified and loaded with radioactive cholesterol as stated earlier, but with different elution
buffer. After washing twice with 600 µL Wash Buffer (200 mM NaCl, 20 mM Tris pH 7, 60 mM imidazole, 
0.004% w/v TritonX-100), the sample was washed with 600 µL Wash Buffer 2 (200 mM NaCl, 20 mM Tris pH 
7, 60 mM imidazole) to remove detergent and eluted with Elution Buffer 3 (200 mM NaCl, 20 mM Mes pH 5.5, 
300 mM imidazole pH 5.5). Approximately 90 pmol loaded sterol-donor protein was transferred to new tubes 
and added 25 pmol, 75 pmol, 150 pmol, 225 pmol or 350 pmol of sterol-acceptor protein (untagged NCR1 
purified in 0.005% DM-NG) in Transfer Buffer (200mM, 20 mM Mes pH 5.5), then added 180 pmol his-tagged 
NPC2 without sterols to limit transfer to micelles, and the total volume was adjusted to 500 µL with Transfer 
Buffer. The samples were incubated for 30 min at 4ºC with gentle shaking. Nickel resin was washed in High pH 
Buffer 2 (200 mM NaCl, 10 mM Tris pH 7.5,), and 150 µL of 50% resin slurry was transferred to each sample 
with 150 µL High pH Buffer 3 (200 mM NaCl, 100 mM Tris pH 11) to increase pH to 7.5. Following 1 hour 
binding at 4ºC, the resin was pelleted (700 g) and the supernatant containing the sterol-acceptor protein from 
each tube was removed and added scintillation liquid. The pelleted resin containing the sterol-donor protein was 
resuspended with Elution Buffer and transferred to a new tube and added scintillation liquid. Both were 
measured in order to quantify the total amount of radioactivity per sample
Fluorescence-based sterol binding assay
NPC2 and NTD proteins were diluted in a modified binding buffer (100 mM NaCl, 50 mM MES pH 5.5) to a 
final concentration of 1 µM in a 0.1 cm thick quartz cuvette. Intrinsic protein fluorescence was excited at 280 nm
and emission was recorded in a wavelength range of 300 to 500 nm. The samples were incubated with increasing
concentrations of DHE, a fluorescent analog of ergosterol, whose excitation spectrum overlaps with the emission
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spectra of aromatic residues of both proteins. Thus, binding of DHE to NPC2 or NTD gives rise to Förster 
resonance energy transfer (FRET) from Tyr and Phe of NPC2 (Figure S3A) and Trp, Tyr and Phe of NTD to 
DHE (Figure S3B), respectively. The final concentration of ethanol in the cuvette for the highest DHE 
concentration of 4 µM was 6%. The incubation time between each of the measurements was 15 min during 
which shutters were closed. The measurements were done using an ISS Chronos spectrofluorometer (Urbana-
Champaign, IL). The slit width was 0.5 mm and no polarizers were used. Separate spectra were recorded for 
DHE in modified binding buffer under identical conditions and subtracted from emission spectra in the presence 
of each protein.
Fluorescence-based sterol transfer assay
NPC2 or NTD proteins were diluted in a modified binding buffer (100 mM NaCl, 50 mM MES pH 5.5) to a final
concentration of 1 µM in a 0.1 cm thick quartz cuvette. Intrinsic fluorescence of NTD was excited at 295 nm and
emission was recorded in a wavelength range of 300 to 500 nm. This excitation wavelength selectively excites 
Trp, which is only present in NTD but not in NPC2. The donor protein was pre-incubated with 1.0 µM DHE, a 
fluorescent analog of ergosterol, whose excitation spectrum overlaps with the emission spectrum of Trp in NTD. 
Thus, binding of DHE to NTD but not to NPC2 gives rise to FRET under these conditions. This can be used to 
advantage as transfer of DHE from NTD to NPC2 results in decrease of FRET, while transfer of DHE from 
NPC2 to NTD results in increased FRET. Donor protein with bound DHE was incubated with increasing 
concentrations (0.1, 0.5, 1.0 and 2.0 µM) acceptor protein, and the rise (for NPC2 to NTD) or decrease (for NTD
to NPC2) in FRET was measured at 390 nm and plotted as function of acceptor concentration. The incubation 
time between each of the measurements was 15 min for pre-equilibration with DHE and 5 min during sterol 
transfer during which shutters were closed. The measurements were done using an ISS Chronos 
spectrofluorometer (Urbana-Champaign, IL). The slit width was 0.5 mm and no polarizers were used. Separate 
spectra were recorded for acceptor protein in the presence of DHE but absence of the donor protein in modified 
binding buffer under identical conditions. These spectra were subtracted from emission spectra of the complete 
transfer mixture, i.e., donor and acceptor protein + DHE ligand.
IN VIVO ASSAYS
In vivo sterol transport assay
The yeast strains used in this study were BY4742 ncr1Δ::KanMX4; BY4742 npc2Δ::KanMX4 and 
BY4741(WT). Yeast strains were grown in YPDade media (2% glucose, 2% peptone, 1% yeast extract, 0.02% 
adenine) overnight to reach an OD600 of 28. Cells were then washed three times with sterile water and diluted to
a final concentration of 0.1 OD600 in YPDade media containing 0.1 µg/mL of FM4-64 dye and 0.1% Tween 80 
with 20 μg/mL DHE. The yeast strains were incubated for 22h with these probes in an oxygen-depleted culture 
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chamber at 30°C to ensure anaerobic conditions and thereby sterol uptake. Subsequently, cells were washed 
three times with PBS. Cells were transferred into media from the first day of growth and cultured under aerobic 
conditions for 0.5h; 6h; 24h or 48h. Before imaging, cells were prepared in a small aliquot to final concentration 
of 1.0 OD600 and incubated for 3min with BODIPY 493/503 (0.5 µg/mL) to stain lipid droplets. Cells were 
washed and imaged. In some experiments, 3 µM Concanamycin A was added in the last 24h before staining lipid
droplets and imaging. Wide-field microscopy was carried out on a Leica DMIRBE microscope with a 63x 1.4 
NA oil immersion objective (Leica Lasertechnik GmbH) with a Lambda SC smart shutter (Sutter Instrument 
Companny) as illumination control. Images were acquired with an Andor Ixon blue EMCCD camera at -75°C. 
DHE was imaged in the UV using a specially designated filter cube (325-nm (20-nm bandpass) exciatation filter,
365-nm dichromatic mirror and 405-nm (40-nm banpass) emission). BODIPY493/503 was imaged using a 
fluorescein filter cube (470-nm [20-nm bandpass] excitation filter, 510-nm longpass dichromatic filter and 537-
nm [23-nm bandpass] emission filter). FM4-64 was imaged using a standard rhodamine filter set (535-nm [50-
nmbandpass] excitation filter, 565-nm longpass dichromatic filter and 610-nm [75-nm bandpass] emission filter).
In case of DHE stacks of 25 images were acquired with 100 msec acquisition time, while for the other probes 
single acquisitions were used. Correction for chromatic aberration between the UV channel and the red and 
green channels was carried out as described previously (Wüstner and Faergeman, 2008). Background and signal 
crossover was independently assessed in unstained or single-labeled samples, respectively. Confocal section 
images were acquired using a Leica SP8 confocal microscope with a 63x oil objective (NA=1.4) and equipped 
with a white light laser (WLL) tunable in the range of 470-700 nm. Fluorescence signals of BODIPY493/503 
(WLL excitation at 488nm, emission at 506-527nm) and of FM4-64 (WLL excitation at 530nm, emission at 555-
644nm) were collected with a hybrid detector.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data from binding and transfer assays were analyzed with either Graph Pad Prism 7 (GraphPad Software Inc., 
San Diego, CA) or SigmaPlot (Systat Software Inc., San José, CA). All experiments were performed at least in 
triplicate. The n for each specific experiment is listed in the relevant figure legend. 
For the radiolabeled binding assays, in order to account for the nonspecific binding, an average of the values 
without protein present were subtracted all data points. A nonlinear regression of a hyperbolic binding model 
(Y=Bmax*X/(Kd+X)) curve was fitted to the data according to:
f = Bmax∙[L]/(KD+[L]) (1)
Here, Bmax is the maximal signal at ligand saturation and [L] is the concentration of the ligand. This model 
assumes that protein concentration is significantly lower than the KD, such that the non-bound ligand 
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approximates the total ligand concentration, [L]. This assumption was met in the radiolabel binding assay. 
Before fitting, the in order to calculate a Bmax and Kd, and the data was normalized to Bmax. For competition 
assays, the data was normalized to cholesterol binding without any competition. Statistical significance was 
calculated using Student's t-test.
In the transfer assays, the amount of transferred cholesterol divided by the total amount of sterol per tube was 
plotted as a function of acceptor protein. In order to account for the natural release of cholesterol, an average of 
transfer to buffer-only was subtracted all data points.
Binding of DHE either protein was measured by fluorescence spectroscopy after subtracting spectra of the 
respective DHE concentration in buffer only. Determination of dissociation constants (i.e., KD values) was 
carried out using the full analytical solution of the one-site binding model for the fractional saturation, f, 
according to:
(2)
Where [RL] is the NPC2- or NTD/ligand complex, [R] is the total concentration of NPC2 or NTD, PT is the total 
protein concentration and [L] is the concentration of the ligand. This model had to be invoked, since the FRET 
assay required higher protein concentrations, such that the approximation of non-bound ligand being close to 
equal the total ligand concentration, [L] does not hold anymore. Before fitting to Eq. 2, all fluorescence 
measurements were normalized according to
(3)
Here F ][�  is the buffer-corrected fluorescence intensity at the given ligand concentration, F 0][�  is the fluorescence 
of the free protein i.e. [L]=0 and � ][���  is the minimum protein intensity in the presence of saturating ligand 
concentration. This data was fitted to Eq. 2 to obtain an estimate for the KD value under each condition.
All image analysis was carried out in ImageJ (Schneider et al., 2012). Images acquired in all three channels (UV 
channel for DHE; green for BODIPY and red channel for FM4-64) were deconvolved by 30 iterations of a 2D-
version of the Richardson Lucy algorithm with a synthetic point spread function, as implemented in the ImageJ 
plugin DeconvolutionLab (Griffa et al., 2010). The contribution of background and autofluorescence in DHE 
images was first assessed by bleach rate imaging, as described previously (Kohut et al., 2011; Solanko et al., 
2018). Correction for these factors and thereby isolation of DHE intensity was achieved by calculating the 
standard deviation at each pixel along the bleach stack. DHE images were subsequently deconvolved as 
described above. For background correction of the green and red channel images, the corresponding routine in 
DeconvolutionLab was used. After processing, images of all three channels were spatially aligned to correct for 
residual chromatic lateral shifts of 1-2 pixels in both directions, and color RGB stacks were generated. For 
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phenotype scoring, regions of interest (ROIs) of 8x8 µm were generated for 40 to 60 cells per RGB stack, and 
automatically arranged in montages of the separate channels. All images for a given channel were processed 
identically and automatically by employing batch processing and self-programmed Macros in ImageJ. Results of
image-based screens on sterol disposition in vacuoles were imported into SigmaPlot (Systat Inc), and the mean 
values of 6 to 8 images with 40 to 100 cells per image were calculated for three independent experiments per 
condition, except wild-type condition which had four independent experiments. The total number of analyzed 
cells were 1126 (wt), 1400 (ΔNCR1), 1807 (ΔNPC2) and 1238 (wt+Con-A). This data was tested for normality 
using a Shapiro Wilk test and for equal variance using a Brown-Forsythe test, and both tests were passed for 
each condition. Statistical significances of differences between the groups were assessed using a Student’s t-test, 
and significance levels are shown in Figure 6B.
DATA AND SOFTWARE AVAILABILITY
Data Resources
The atomic coordinates and structure factors have been deposited in the Protein Data Bank with the accession 
code 6R4L for NCR1, and 6R4M for sterol-free NPC2(crystal structure), and 6R4N for sterol-bound NPC2. The 
7.2 Å EM map for NCR1 have been deposited in EMDB with accession code EMD-4771.
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Supplemental Excel table titles and legends
Table S1. Statistics for crystallographic data collection and structure refinement, Related to Figure 1 and 
Figure 3.
Table S2. Niemann-Pick Disease type C missense mutations identified in literature, Related to Figure 4 
and Figure 7
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NPC disease mutations 
functional catagorization
Name NCR1 NPC2 sterol-free NPC2 sterol-bound NPC2 Derivative 1 NPC2 Derivative 2
Type native native native Ta6Br12 derivative Ta6Br12 derivative
Data Collection
Space group C2 P6(1) P6(1) P6(1) P6(2)
Cell dimensions
    a. b, c (Å) 148.7, 90.1, 161.7 205.3, 205.3, 39.1 215.4, 215.4, 129.8 215.5, 215.5, 129.2 194.7, 194.7, 41.3
    alpha, beta, gamma (deg) 90.0, 110.3, 90.0 90.0, 90.0, 120.0 90.0, 90.0, 120.0 90.0, 90.0, 120.0 90.0, 90.0, 120.0
Monomers per asym. unit. 1 3 9 9 9
Wavelenght (Å) 0.97950 0.97242 0.96864 1.25455 0.97950
Number of reflections measured 43210 88962 880077 540139 178433
Number of unique reflections 23939 23777 75864 100761 16854
Resolution (Å) 44.45-2.8 (2.9-2.8) 48.05-2.9 (3.0-2.9) 49.7-3.3 (3.4-3.3) 56.2-3.9 (4.0-3.9)
Rmeas (%) 7.7 (172.5) 9.16 (168.8) 34.56 (324.2) 22.8 (176.5) 15.4 (378.4)
8.55 (0.81) 9.15 (0.73) 8.3 (0.85) 5.49 (0.73) 10.4 (1.3)
CC(1/2) 99.9 (42.8) 99.8 (36.7) 99.3 (27.9) 99.5 (35.6) 99.3 (81.5)
Completeness (%) 93.5 (96.4) 99.54 (99.4) 99.91 (99.93) 99.9 (99.7) 99.60 (99.87)
Redundancy 1.8 (1.8) 3.7 (3.2) 11.6 (11.6) 5.4 (5.4) 11.2 (10.7)
Wilson B-factor (Å) 134 90 66
Refinement
Resolution (Å) 49.12-3.5 (3.6-3.5) 44.45-2.8 (2.9-2.8) 48.05-2.9 (3.0-2.9)
No. reflections (work/free) 22663/1209 22585/1197 73868/1990
Rwork (%) 26.56 (37.31) 23.63 (37.28) 22.58 (34.31)
Rfree (%) 30.12 (41.81) 26.18 (40.78) 25.67 (36.50)
No. of Atoms
    Protein 8759 3389 10121
    Ergosterol 29 n/a 145
    Carbohydrates / Ions 106 42 220
Average B Factors (Å)
    Overall 158 108 70
    Protein 157 107 68
    Ergosterol 157 n/a 93
    Carbohydrates / Ions 231 172 131
RMSD
    Bond lenghts (Å) 0.010 0.007 0.011
    Bond angles (deg) 1.12 1.25 1.42
Ramachandran Plot Statistics
    Favored regions 92.1 96.0 97.0
    Allowed regions 7.7 3.5 2.9
    Disallowed regions 0.2 0.5 0.1
Deposited model (PDB id) 6R4L 6R4M 6R4N
Table S1. Statistics for crystallographic data collection and structure refinement. Related to Figure 1 and Figure 3
49.12-3.5 (3.625-3.5)a
Mean I/σ(I)
aHighest resolution shell is shown in parenthesis.
Location References [PMID]
63 C → R NTD Surface C64 Meiner V et al. (2001) [11545687]
74 C → Y NTD Surface C75 Park WD et al. (2003) [12955717]
92 Q → R NTD Surface P93 Sun X et al. (2001) [11349231]; Ribeiro I et al. (2001) [11479732]
113 C → R NTD Surface C114 Blom TS et al. (2003) [12554680]
137 T → M NTD Surface D133 Sun X et al. (2001) [11349231]; Fernandez-Valero EM et al. (2005) [16098014]; Akizu N et al. (2013) [23453666]
166 P → S NTD Sterol Pathway S162 Park WD et al. (2003) [12955717]; Millat G et al. (2005) [16126423]
177 C → G NTD Sterol Pathway G174 Yamamoto T et al. (2000) [11182931]
177 C → Y NTD Sterol Pathway G174 Ribeiro I et al. (2001) [11479732]; Fernandez-Valero EM et al. (2005) [16098014]; Millat G et al. (2005) [16126423]
215 H → R NTD Surface K211 Wassif CA et al. (2016) [25764212]
222 N → S NTD Surface D218 Park WD et al. (2003) [12955717]
231 V → G NTD Surface - Kaminski WE et al. (2002) [12408188]
242 D → H NTD Surface D234 Millat G et al. (2001) [11333381]
242 D → N NTD Surface D234 Sun X et al. (2001) [11349231]
247 C → Y NTD Surface C239 Park WD et al. (2003) [12955717]
248 G → V NTD Surface P240 Sun X et al. (2001) [11349231]
272 M → R M1 helix Surface V262 Millat G et al. (2001) [11333381]
372 R → W MLD Pincer movement T361 Fernandez-Valero EM et al. (2005) [16098014]
378 V → A MLD Sterol Pathway I367 Millat G et al. (2001) [11333381]
380 L → F MLD Sterol Pathway L369 Park WD et al. (2003) [12955717]
388 A → P MLD Pincer movement K377 Park WD et al. (2003) [12955717]
389 R → C MLD Pincer movement F378 Park WD et al. (2003) [12955717]
401 P → T MLD Sterol Pathway P390 Sun X et al. (2001) [11349231]
404 R → P MLD Sterol Pathway R393 Millat G et al. (2005) [16126423]
404 R → Q MLD Sterol Pathway R393 Sun X et al. (2001) [11349231]; Millat G et al. (2001) [11333381]; Meiner V et al. (2001) [115456879]
404 R → W MLD Sterol Pathway R393 Park WD et al. (2003) [12955717]
433 P → L MLD Surface P405 Park WD et al. (2003) [12955717]
434 P → L MLD Surface V406 Fernandez-Valero EM et al. (2005) [16098014]
451 E → K MLD Surface T423 Tarugi P et al. (2002) [12401890]
473 S → P MLD Surface E443 Yamamoto T et al. (2000) [11182931]
474 P → L MLD Surface - Fernandez-Valero EM et al. (2005) [16098014]; Tarugi P et al. (2002) [12401890]
479 C → Y MLD Surface C447 Fernandez-Valero EM et al. (2005) [16098014]
509 Y → S MLD Surface W466 Park WD et al. (2003) [12955717]
510 H → P MLD Surface K467 Yamamoto T et al. (2000) [11182931]
512 H → R MLD Surface E469 Bauer P et al. (2002) [11754101]
518 R → Q MLD Sterol Pathway K475 Yamamoto T et al. (2000) [11182931]; Millat G et al. (2001) [11333381]
518 R → W MLD Sterol Pathway K475 Ribeiro I et al. (2001) [11479732]; Gong X et al. (2016) [27238017]
521 A → S MLD Sterol Pathway V478 Park WD et al. (2003) [12955717]
537 F → L MLD Surface F483 Millat G et al. (2005) [16126423]
543 P → L MLD Sterol Pathway T490 Park WD et al. (2003) [12955717]; Millat G et al. (2005) [16126423]
576 K → R MLD Surface - Fernandez-Valero EM et al. (2005) [16098014]
605 A → V MLD Sterol Pathway T544 Millat G et al. (2001) [11333381]
612 E → D MLD Pincer movement E551 Sun X et al. (2001) [11349231]
615 R → C MLD Pincer movement N554 Millat G et al. (2005) [16126423]
615 R → L MLD Pincer movement N554 Park WD et al. (2003) [12955717]; Millat G et al. (2005) [16126423]
628 Y → C SSD Pincer movement Y565 Garver WS et al. (2010) [19744920]
631 M → R SSD Protonation site M567 Millat G et al. (2005) [16126423]; Millat G et al. (2001) [11333381]
640 G → R SSD Pincer movement R577 Park WD et al. (2003) [12955717]
652 S → W SSD Pincer movement T583 Sun X et al. (2001) [11349231]
660 G → S SSD Sterol Pathway G591 Park WD et al. (2003) [12955717]
664 V → M SSD Sterol Pathway V595 Park WD et al. (2003) [12955717]; Fernandez-Valero EM et al. (2005) [16098014]
666 S → N SSD Sterol Pathway A597 Dvorakova L et al. (2006) [16802107]
670 C → W SSD Pincer movement C601 Bauer P et al. (2002) [11754101]
673 G → V SSD Pincer movement G604 Park WD et al. (2003) [12955717]
684 L → F SSD Sterol Pathway L615 Park WD et al. (2003) [12955717]
691 P → L SSD Sterol Pathway P622 Park WD et al. (2003) [12955717]
695 L → V SSD Sterol Pathway L626 Park WD et al. (2003) [12955717]
700 D → N SSD Protonation site D631 Park WD et al. (2003) [12955717]
703 F → S SSD Protonation site F634 Yamamoto T et al. (2000) [11182931]
724 L → P SSD Pincer movement I656 Millat G et al. (2001) [11333381]
727 V → F SSD Pincer movement A659 Fernandez-Valero EM et al. (2005) [16098014]
734 S → I SSD Protonation site S665 Park WD et al. (2003) [12955717]
742 E → K SSD Protonation site Q674 Park WD et al. (2003) [12955717]
745 A → E SSD Protonation site C677 Park WD et al. (2003) [12955717]
754 M → K SSD Pincer movement M685 Fernandez-Valero EM et al. (2005) [16098014]
763 F → L SSD Pincer movement Y695 Millat G et al. (2005) [16126423]
767 A → V SSD Pincer movement S699 Park WD et al. (2003) [12955717]
775 Q → P SSD Protonation site Q707 Fernandez-Valero EM et al. (2005) [16098014]; Millat G et al. (2001) [11333381]
789 R → C SSD Pincer movement R721 Sun X et al. (2001) [11349231]
789 R → G SSD Pincer movement R721 Park WD et al. (2003) [12955717]
825 Y → C SSD Pincer movement Y742 Sun X et al. (2001) [11349231]; Millat G et al. (2005) [16126423]; Millat G et al. (2001) [11333381]; Bauer P et al. (2002) [11754101]
849 S → I SSD Pincer movement S763 Bauer P et al. (2002) [11754101]
862 Q → L CTD Sterol Pathway Q776 Millat G et al. (2005) [16126423]
865 S → L CTD Sterol Pathway A779 Fernandez-Valero EM et al. (2005) [16098014]; Millat G et al. (2005) [16126423]
871 Y → C CTD Pincer movement Y785 Millat G et al. (2005) [16126423]
874 D → V CTD Pincer movement D788 Sun X et al. (2001) [11349231]; Kaminski WE et al. (2002) [12408188]; Millat G et al. (2001) [11333381]; Bauer P et al. (2002) [11754101]
887 P → L CTD Pincer movement P801 Garver WS et al. (2010) [19744920]
888 P → S CTD Sterol Pathway P802 Sun X et al. (2001) [11349231]
889 V → M CTD Sterol Pathway V803 Yamamoto T et al. (2000) [11182931]
890 Y → C CTD Sterol Pathway Y804 Tarugi P et al. (2002) [12401890]
899 Y → D CTD Sterol Pathway L812 Tarugi P et al. (2002) [124018909
910 G → S CTD Sterol Pathway G823 Tarugi P et al. (2002) [12401890]
917 D → Y CTD Surface D831 Millat G et al. (2005) [16126423]
Table S2 - Niedmann-Pick Disease type C missense mutations identified in literature. Related to Figure 4 and Figure 6
Human NPC1 
residue
Disease 
mutation
Functional 
catagorization
Corresponding 
residue in NCR1a
923 I → V CTD Surface L837 Garver WS et al. (2010) [19744920]
926 A → T CTD Sterol Pathway E840 Fernandez-Valero EM et al. (2005) [16098014]
927 A → V CTD Sterol Pathway R841 Meiner V et al. (2001) [11545687]
928 Q → P CTD Sterol Pathway H842 Carstea ED et al. (1997) [9211849]
929 L → P CTD Surface - Sun X et al. (2001) [11349231]
934 R → Q CTD Surface T845 Millat G et al. (2005) [16126423]; Millat G et al. (2001) [11333381]; Greer WL et al. (1999) [10521290]
940 S → L CTD Sterol Pathway A851 Sun X et al. (2001) [11349231]; Millat G et al. (2005) [16126423]; Greer WL et al. (1999) [10521290]
942 W → C CTD Sterol Pathway W853 Ribeiro I et al. (2001) [11479732]; Fernandez-Valero EM et al. (2005) [16098014]
943 I → M CTD Sterol Pathway L854 Millat G et al. (2001) [11333381]
944 D → N CTD Sterol Pathway D855 Sun X et al. (2001) [11349231]; Fernandez-Valero EM et al. (2005) [16098014]; Millat G et al. (2001) [11333381]
945 D → N CTD Sterol Pathway D856 Park WD et al. (2003) [12955717]
948 D → H CTD Sterol Pathway M859 Fernandez-Valero EM et al. (2005) [16098014]
948 D → N CTD Sterol Pathway M859 Sun X et al. (2001) [11349231]; Kaminski WE et al. (2002) [12408188]; Greer WL et al. (1999) [10521290]
948 D → Y CTD Sterol Pathway M859 Bauer P et al. (2002) [11754101]
950 V → M CTD Surface L861 Millat G et al. (2005) [16126423]; Millat G et al. (2001) [11333381]
954 S → L CTD Surface D866 Yamamoto T et al. (2000) [11182931]; Bauer P et al. (2002) [11754101]; Greer WL et al. (1999) [10521290]
956 C → Y CTD Surface C868 Yamamoto T et al. (2000) [11182931]
958 R → L CTD Surface Y870 Bauer P et al. (2002) [11754101]
958 R → Q CTD Surface R870 Sun X et al. (2001) [11349231]
959 V → E CTD Surface L871 Fernandez-Valero EM et al. (2005) [16098014]
961 N → S CTD Surface K873 Dvorakova L et al. (2006) [16802107]
968 N → S CTD Surface P880 Millat G et al. (2005) [16126423]; Yang CC et al. (2005) [15774455]
976 C → R CTD Surface C888 Sun X et al. (2001) [11349231]
978 R → C CTD Surface T890 Sun X et al. (2001) [11349231]; Ribeiro I et al. (2001) [11479732]
986 G → S CTD Surface N898 Millat G et al. (2001) [11333381]
992 G → A CTD Surface G907 Millat G et al. (2005) [16126423]
992 G → R CTD Surface G907 Millat G et al. (2001) [11333381]; Millat G et al. (2005) [16126423]
992 G →W CTD Surface G907
996 M →R CTD Surface M911 Yamamoto T et al. (2000) [11182931]
1004 S → L CTD Surface N919 Sun X et al. (2001) [11349231]
1007 P → A CTD Sterol Pathway S922
1012 G → D CTD Sterol Pathway P926 Meiner V et al. (2001) [11545687]
1015 G → V CTD Sterol Pathway G929 Yang CC et al. (2005) [15774455]
1016 H → R CTD Sterol Pathway R930 Park WD et al. (2003) [12955717]
1023 V → G CTD Sterol Pathway L937 Sun X et al. (2001) [11349231]
1034 G → R CTD Sterol Pathway S945 Yang CC et al. (2005) [15774455]
1035 A → V CTD Sterol Pathway A946 Ribeiro I et al. (2001) [11479732]; Fernandez-Valero EM et al. (2005) [16098014]
1036 T → K CTD Sterol Pathway S947 Fernandez-Valero EM et al. (2005) [16098014]
1036 T → M CTD Sterol Pathway S947 Fernandez-Valero EM et al. (2005) [16098014]; Millat G et al. (2005) [16126423]
1054 A → T CTD Pincer movement A965 Millat G et al. (2001) [11333381]
1059 R → Q CTD Pincer movement V970 Park WD et al. (2003) [12955717]
1061 I → T CTD Surface I972
1062 A → V CTD Surface S973 Millat G et al. (2005) [16126423]
1066 T → N CTD Surface P977 Fernandez-Valero EM et al. (2005) [16098014]
1087 F → L CTD Sterol Pathway F990 Park WD et al. (2003) [12955717]
1088 Y → C CTD Sterol Pathway F991 Yamamoto T et al. (2000) [11182931]
1089 E → K CTD Sterol Pathway V992 Sun X et al. (2001) [11349231]
1094 I → T SSD-like Pincer movement L997 Kaminski WE et al. (2002) [12408188]
1097 D → N SSD-like Pincer movement L1000 Millat G et al. (2005) [16126423]
1137 N → I SSD-like Pincer movement D1039 Park WD et al. (2003) [12955717]
1140 G → V SSD-like Pincer movement A1042 Park WD et al. (2003) [12955717]
1142 M → T SSD-like Pincer movement M1044 Sun X et al. (2001) [11349231]; Millat G et al. (2001) [11333381]
1150 N → K SSD-like Pincer movement N1052 Sun X et al. (2001) [11349231]
1151 A → T SSD-like Pincer movement A1053 Garver WS et al. (2010) [19744920]
1156 N → I SSD-like Protonation site N1058 Fernandez-Valero EM et al. (2005) [16098014]
1156 N → S SSD-like Protonation site N1058
1165 V → M SSD-like Protonation site V1067 Sun X et al. (2001) [11349231]
1167 F → L SSD-like Protonation site F1069 Imrie J et al. (2007) [17160617]
1168 C → Y SSD-like Protonation site C1070 Millat G et al. (2001) [11333381]
1174 A → V SSD-like Pincer movement S1076 Millat G et al. (2005) [16126423]
1186 R → H SSD-like Pincer movement R1091 Sun X et al. (2001) [11349231]; Millat G et al. (2005) [16126423]; Millat G et al. (2001) [11333381]
1189 E → G SSD-like Pincer movement Y1094 Sun X et al. (2001) [11349231]
1205 T → K SSD-like Protonation site T1110 Park WD et al. (2003) [12955717]
1205 T → R SSD-like Protonation site T1110 Yamamoto T et al. (2000) [11182931]
1212 V → L SSD-like Pincer movement V1117 Yang CC et al. (2005) [15774455]
1213 L → V SSD-like Pincer movement L1118 Greer WL et al. (1999) [10521290]
1213 L → F SSD-like Pincer movement L1118 Yamamoto T et al. (2000) [11182931]
1216 A → V SSD-like Pincer movement A1121 Millat G et al. (2005) [16126423]
1224 F → L SSD-like Pincer movement F1126 Fernandez-Valero EM et al. (2005) [16098014]
1236 G → E SSD-like Protonation site A1141 Yamamoto T et al. (2000) [11182931]
1240 G → R SSD-like Protonation site A1145 Millat G et al. (2005) [16126423]
1249 S → G SSD-like Pincer movement S1154 Park WD et al. (2003) [12955717]
Meiner V et al. (2001) [11545687]; Millat G et al. (2005) [16126423]; Tarugi P et al. (2002) [12401890]; Greer WL (1999) [10521290]; 
Greer WL (1998) [9634529]
Ribeiro I et al. (2001) [11479732]; Fernandez-Valero EM et al. (2005) [16098014]; Millat G et al. (2005) [16126423]; Millat G et al. (2001) 
[11333381]; Tarugi P et al. (2002) [12401890]; Bauer P et al. (2002) [11754101]; Greer WL et al. (1999) [10521290]
Sun X et al. (2001) [11349231]; Ribeiro I et al. (2001) [11479732]; Fernandez-Valero EM et al. (2005) [16098014]; Millat G et al. (2005) 
[16126423]; Yamamoto T et al. (2000) [11182931]; Millat G et al. (2001) [11333381]; Tarugi P et al. (2002) [12401890]; Bauer P et al. 
(2002) [11754101]; Greer WL et al. (1999) [10521290]; Millat G et al. (1999) [10521297]
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